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ABSTRACT 
 
Breast cancer is the most common malignancy and the leading cause of cancer death in 
women. Systemic breast cancer therapies include 1) hormone therapy, 2) immunotherapy, 
and 3) chemotherapy. Chemotherapy is commonly used in combination with 
immunotherapy, achieving synergistic activity by multiple mechanisms specific to the 
type of breast cancer. However, the efficacy of anticancer drugs has been limited by their 
toxic side effects in normal cells and drug resistance acquired by cancer cells. Therefore, 
the development of a novel treatment strategy for the selective delivery of therapeutic 
agents to breast cancer cells is crucial to improve the therapeutic index and 
efficacy/toxicity balance. The objective of this project is to develop multi-functional 
polymeric nanotherapeutics for breast cancer therapy that specifically target malignant 
cells and provide combinatorial delivery of an anticancer drug and therapeutic nucleic 
acid designed to reduce the expression of proteins responsible for drug resistance. These 
multi-functional polymeric nanotherapeutics will consist of three functional components 
1) folate (FA) as a targeting moiety to deliver these nanotherapeutics to FA receptor 
alpha-positive breast cancer cells (FA receptor is over-expressed in 32% of breast 
cancers), 2) small interfering RNA (siRNA) designed against multidrug resistant protein 
(ABCB1), a gene responsible for drug resistance in cancer cells, and 3) the 
chemotherapeutic, Doxorubicin (DOX). The efficacy of these targeted multifunctional 
nanotherapeutics will be evaluated in FA-receptor alpha positive (FA+) drug resistant 
breast cancer cells.  
 
 iii 
To achieve this goal, FA-functionalized polymeric micelle nanoparticles, folate-
polyethylenimine-graft-poly (lactide-co-glycolide) (FA-PgP) were designed as a targeted 
drug and nucleic acid delivery carrier. We synthesized and characterized FA-PgP and 
demonstrated that the FA-PgP polymeric micelle is a promising carrier for plasmid DNA 
capable of transfecting breast cancer (MCF-7, MDA-MB-435 Wild Type, and MDA-MB-
435 DOX resistant) cells in media containing 10% serum. We also demonstrated that FA-
PgP exhibited selectivity by comparing transfection efficiencies in folate receptor alpha 
positive (MCF-7, MDA-MB-435 Wild Type, and MDA-MB-435 DOX resistant) and 
negative breast cancer cell lines (MDA-MB-468) in vitro and demonstrated that PgP can 
deliver pGFP (plasmid encoding green fluorescence protein) and pbGal (plasmid 
encoding beta-	galactosidase gene) as reporter genes efficiently in an athymic Nu/Nu 
mouse drug resistant breast tumor model. Finally, Doxorubicin loaded FA-PgP was able 
to induce increased or similar cytotoxicity compared its free drug counterpart in MCF-7 
and MDA-MB-435 DOX resistant lines and over a LD50 response in MDA-MB-468 and 
MDA-MB-435 Wild Type cells. Furthermore, FA-PgP exhibited FA+ related selectivity 
in all breast cancer cell lines tested. Future work includes utilizing therapeutic siRNAs 
targeting ABCB1 with FA-PgP to overcome drug resistance in breast cancers. 
  
 iv 
ACKNOWLEDGMENTS 
 
 
Thanks to Dr. Angela Alexander-Bryant for her help with everything, especially the data 
and manuscript drafting. Thanks to Dr. So-Jung Gwak, Breanne Hourigan, Justin Nice, 
Christian Macks, and Erica Beal for all their in-lab work and support 
 v 
TABLE OF CONTENTS 
 
 
Page 
 
TITLE PAGE .................................................................................................................... i 
 
ABSTRACT ..................................................................................................................... ii 
 
ACKNOWLEDGMENTS .............................................................................................. iv 
 
LIST OF TABLES ......................................................................................................... vii 
 
LIST OF FIGURES ...................................................................................................... viii 
 
CHAPTER 
 
 I. INTRODUCTION ......................................................................................... 1 
 
   What is Cancer? ....................................................................................... 1 
   Drug Resistance and its Challenges ......................................................... 4 
   Polymeric Micelles .................................................................................. 8 
   General Hurdles Regarding DDV .......................................................... 12 
   Need for Increased Specificity ............................................................... 16 
   Need for a Multifunctional DDV ........................................................... 22 
 
 II. RESEARCH OBJECTIVES ........................................................................ 23 
 
   Project Rationale .................................................................................... 23 
   Specific Aims ......................................................................................... 25 
 
 III. SYNTHESIS AND CHARACTERIZATION POLY(LACTIDE- 
  CO-GLYCOLIDE)-GRAFT-POLYETHYLENIMINE (PgP) 
  AS A NUCLEIC ACID CARRIER ............................................................. 28 
 
        Introduction ............................................................................................ 28 
        Materials and Methods ........................................................................... 37  
                        Results and Discussion .......................................................................... 46 
   Conclusions ............................................................................................ 67 
    
 IV. EVALUATE POLY(LACTIDE-CO-GLYCOLIDE)-GRAFT- 
  POLYETHYLENIMINE (PgP) AS A DRUG CARRIER .......................... 69 
 
   Introduction ............................................................................................ 69 
 vi 
Table of Contents (Continued) 
 
Page 
 
   Materials and Methods ........................................................................... 70 
   Results and Discussion .......................................................................... 73 
   Conclusions ............................................................................................ 80 
    
 V. SYNTHESIZE AND CHARACTERIZE FOLATE FUNCTIONALIZED 
POLY(LACTIDE-CO-GLYCOLIDE)-GRAFT-POLYETHYLENIMINE 
NANOPARTICLES (FA-PgP) AS DRUG AND siRNA CARRIER  
  FOR COMBINATORIAL THERAPY FOR THE EFFICIENT  
  TREATMENT OF VARIOUS TYPES OF BREAST CANCER  
  CELLS IN VITRO ....................................................................................... 82 
 
   Introduction ............................................................................................ 82 
   Results and Discussion .......................................................................... 97 
   Conclusions .......................................................................................... 126 
 
REFERENCES ............................................................................................................ 127 
 vii 
LIST OF TABLES 
 
 
Table                                                                                                                               Page 
 
 3.1 Table summarizing composition of PgP-(12k, 25k, 50k) ............................ 48 
 
 4.1 Table summarizing Doxorubicin loading in PgP-[12k, 25k, 50k]  
  at 1 mg/mL with 1 mg/mL DOX ................................................................. 74 
 
 4.2 Table summarizing relative Doxorubicin loading amounts in  
  PgP-[12k, 25k, 50k] ..................................................................................... 74 
 
 5.1 Table summarizing Doxorubicin loading in PgP-12k, FA-PgP-12k,  
  and mixed micelles comprised of one part FA-PgP-12k to two parts  
  PgP-12k by weight ..................................................................................... 119 
  
 viii 
LIST OF FIGURES 
 
 
Figure                                                                                                                             Page 
 
 1.1 Descriptions of cell lines. Estrogen receptor, Progesterone receptor,  
  Human Epidermal Factor-2 absences together represent cell lines  
  that are triple negative breast cancers .......................................................... 21 
 
 3.1 F1H-NMR spectra of PgP-[12k, 25k, 50k] (A) PgP-12k (B)  
  PgP-25k (C). PgP-50k .................................................................................. 47 
 
 3.2 Particle size and zeta potential of PgP-(12k, 25k, 50k) and  
  PEI polyplexes o .......................................................................................... 50 
 
 3.3 A) Gel retardation assay using PgP-(12k, 25k, 50k) /pGFP complexes.  
  Lane 1: DNA ladder, Lane 2: naked pDNA, Lane 3 -9: PgP/pGFP  
  (N/P: 2.5, 5, 10, 15, 20, 25, 30 respectively) B) DNase protection assay  
  with PgP-(12k, 25k, 50k)/pGFP complexed at N/P 25/1. Lane 1: pGFP,  
  Lane 2: pGFP with 2 units DNase, Lane 3: PgP-12k/pGFP, Lane 4:  
  PgP-12k/pGFP with 2 units DNase, Lane 5: PgP-25k/pGFP, Lane 6:  
  PgP-25k/pGFP with 2 units DNase, Lane 7: PgP-50k/pGFP, Lane 8:  
  PgP-50k/pGFP with 2 units DNase C) Heparin competition assay  
 using PgP-(12k, 25k, 50k) /pGFP complexes. Lane 1: DNA ladder,  
Lane 2: naked pDNA, Lane 3: PgP/pGFP (N/P:25/1), Lanes 4-10:  
PgP-12k/pGFP (N/P: 25/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 
respectively) ................................................................................................. 52 
 
 3.4 A) Hemolytic activity of PEI, PgP-[12k, 25k, 50k] at 0.025, 0.05,  
  0.1, 0.25, 0.5, 0.75, 1 mg/mL in 7.4 pH 150 mM phosphate buffered  
  saline (PBS). Red blood cells collected from Sprague-Dawley rats.  
  * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 B) Hemoaggregation  
  of red blood cells in 7.4 pH 150 mM PBS incubated with 1 mg/mL of  
  PEI, PgP-[12k, 25k, 50k] for fifteen minutes .............................................. 54 
 
 3.5 Transfection efficiency (primary axis) and metabolic activity  
  (secondary axis) of three PgP /pGFP complexes at varying N/P  
  ratios in (A) MCF-7, (B) MDA-MB-468, (C) MDA-MB-435 Wild Type,  
  and (D) MDA-MB-435 ADR cells.  * or ## P≤ 0.05, ** or ## P≤0.01,  
  *** or ### P≤0.001, **** or #### P≤0.0001 .............................................. 56 
 
 3.6 Time-course study of GFP expression in MCF-7 cells with PEI/pGFP  
  and PgP-12k/pGFP in 10% serum condition at 4, 8, 14, 20 days.  
  Top: PEI/pGFP N/P 5/1, Bottom: PgP/pGFP N/P 30/1d ............................. 58 
 ix 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 3.7 Confocal microscopy depicting intracellular trafficking of Rhodamine-
PgP/pGFP polyplexes in MDA-MB-435 WT and MDA-MB-435 ADR  
  breast cancer cells ........................................................................................ 59 
 
 3.8 Metabolic activity of three PgP /pGFP complexes in (A) MCF-7,  
  (B) MDA-MB-468, (C) MDA-MB-435 Wild Type, and  
  (D) MDA-MB-435 ADR cells. PgP/pGFP complexes were formed  
  at N/P 25/1 and both PgP alone and PgP/pGFP complexes were  
  diluted down to concentration of PgP found in designated N/P  
  equivalent  * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 ................ 63 
 
 3.9 Cell uptake of siGLO/PgP complexes in MDA-MB-435 ADR  
  cells (A)% uptake (B) mean fluorescence value (F) .................................... 65 
 
 3.10 Transfection efficacy of PEI/pβGal and PgP-12k/pβGal in  
  MDA-MB-435 ADR cells ............................................................................ 66 
 
 3.11 GFP expression after local injection of PgP12k/pGFP in mice,  
  excised tumor and organs at 1week post-injection ...................................... 66 
 
     3.12  Transfection efficacy of PEI/pβGal and PgP-12k/pβGal in 
  MDA-MB-435 ADR tumors ........................................................................ 67 
 
 4.1 (A) Doxorubicin loading in PgP-(12k,25k,50k) (B) Doxorubicin  
  loading efficiency in PgP-(12k, 25k, 50k) ................................................... 73 
 
 4.2 Cytotoxicity of Doxorubicin HCl, PgP-(12k, 25k, 50k), PgP- 
  (12k, 25k, 50k) /pGFP, Doxorubicin loaded PgP-[12k, 25k, 50k],  
  Doxorubicin loaded PgP-(12k, 25k, 50k) /pGFP complexes in (A)  
  MCF-7, (B) MDA-MB-468, (C) MDA-MB-435 Wild Type, and (D)  
  MDA-MB-435 ADR cells. Concentration of Doxorubicin HCl used  
  was equivalent to amount of Doxorubicin used in DOX loaded PgP  
  groups. PgP/pGFP complexes were formed at N/P 25/1 and both PgP  
  alone and PgP/pGFP complexes were diluted down to concentration  
  of PgP used in designated N/P equivalent. * P≤ 0.05, ** P≤0.01,  
  *** P≤0.001, **** P≤0.0001 vs control, * P≤ 0.05, ** P≤0.01,  
  *** P≤0.001, **** P≤0.0001 vs PgP or PgP/pGFP counterpart,  
  é P≤ 0.05, éé P≤0.01, ééé P≤0.001, éééé P≤0.0001 vs  
  equivalent DOX HCl dose ........................................................................... 77 
 
 x 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 5.1 Scheme of synthesis of generic FA-PgP ...................................................... 87 
 
 5.2 1H-NMR spectra of FA-PgP-12k ................................................................. 98 
 
 5.3 Gel retardation assay using PgP-12k, FA-PgP-12k, one part  
FA-PgP-12k to two parts PgP-12k by weight, and one part  
FA-PgP-12k to four parts PgP-12k by weight /pGFP complexes.  
Lane 1: DNA ladder, Lane 2:naked pDNA, Lane 3 -9: PgP/pGFP  
(N/P: 2.5, 5, 7.5, 10, 12.5, 15, 17.5 respectively) ........................................ 99 
 
 5.4a Heparin competition assay using PgP-12k, FA-PgP-12k, one  
  part FA-PgP-12k to two parts PgP-12k by weight, and one part  
  FA-PgP-12k to four parts PgP-12k by weight /pGFP /pGFP  
  complexes. Lane 1: DNA ladder, Lane 2:naked pDNA, Lane 3:  
  PgP/pGFP (N/P:15/1), Lanes 4-10: PgP-12k/pGFP (N/P: 15/1  
  with W/W Heparin 1, 2, 5, 10, 20, 40, 100 respectively) .......................... 100 
 
 5.4b Heparin competition assay using PgP-12k, FA-PgP-12k/pGFP  
  complexes N/P 30/1 Lane 1: DNA ladder, Lane 2:naked pDNA,  
  Lane 3: PgP/pGFP (N/P:30/1), Lanes 4-10: PgP-12k/pGFP  
  (N/P: 30/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 respectively .......... 101 
 
 5.4c FA-PgP-12k and one part FA-PgP-12k to two parts PgP-12k by  
  weight/pGFP complexes. Lane 1: DNA ladder, Lane 2:naked  
  pDNA, Lane 3: PgP/pGFP (N/P:25/1), Lanes 4-10: PgP-12k/pGFP  
  (N/P: 25/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 respectively) ........ 102 
 
 5.5 Gel retardation assay using PgP-12k, FA-PgP-12k, one part  
  FA-PgP-12k to two parts PgP-12k by weight, and one part  
  FA-PgP-12k to four parts PgP-12k by weight /siABCB1 complexes.  
  Lane 1: DNA ladder, Lane 2:naked siABCB1, Lane 3 -9:  
  PgP/siABCB1 (N/P: 2.5, 5, 10, 12.5, 15, 17.5, 20, 22.5, 25  
  respectively) ............................................................................................... 103 
 
 5.6a Heparin competition assay using PgP-12k, FA-PgP-12k, one  
  part FA-PgP-12k to two parts PgP-12k by weight, and one part  
  FA-PgP-12k to four parts PgP-12k by weight / siABCB1 complexes.  
  Lane 1: DNA ladder, Lane 2:naked siABCB1, Lane 3: PgP/ siABCB1 
(N/P:15/1), Lanes 4-10: PgP-12k/ siABCB1 (N/P: 15/1 with W/W  
  Heparin 1, 2, 5, 10, 20, 40, 100 respectively ............................................. 105 
 xi 
 
 
 
 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 5.6b Heparin competition assay using PgP-12k/ siABCB1 complexes.  
  Lane 1: DNA ladder, Lane 2:naked siABCB1, Lane 3: PgP/  
  siABCB1 (N/P:30/1), Lanes 4-10: PgP-12k/ siABCB1 (N/P:  
  30/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 respectively) .................. 106 
 
 5.6c Heparin competition assay using PgP-12k, FA-PgP-12k / siABCB1 
complexes. Lane 1: DNA ladder, Lane 2:naked siABCB1, Lane 3:  
  PgP/ siABCB1 (N/P:60/1), Lanes 4-10: PgP-12k/ siABCB1 (N/P:  
  60/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 respectively) .................. 106 
 
 5.7 (A) Hemolytic activity of PEI, PgP-12k, and FA-PgP-12k at 0.025,  
  0.05, 0.1, 0.25, 0.5, 0.75, 1 mg/mL in 7.4 pH 150 mM phosphate  
  buffered saline (PBS). Red blood cells collected from Sprague-Dawley  
  rats. (B) Hemoaggregation of red blood cells in 7.4 pH 150 mM PBS  
  incubated with 1 mg/mL of PEI, PgP-12k, or FA-PgP-12k for  
  fifteen minutes ........................................................................................... 108 
 
 5.8 Transfection efficiency of PEI, FA-PEI (N/P: 5/1), PgP-12k/pGFP,  
  FA-PgP-12k/pGFP, mixed micelles comprised of one part FA-PgP-12k  
  to two parts PgP-12k by weight, (N/P: 25/1) in (A) MCF-7, (B) MDA- 
  MB-468, (C) MDA-MB-435 Wild Type, and (D) MDA-MB-435 ADR  
  cells. Groups designated with “INHIB” were co incubated with (0.33  
  mg/mL free folate)  * P≤ 0.05, ** P≤0.01, *** P≤0.001,  
  **** P≤0.0001 ........................................................................................... 110 
 
 5.9 Metabolic activity of PEI, FA-PEI (N/P: 5/1), PgP-12k/pGFP,  
  FA-PgP-12k/pGFP, mixed micelles comprised of one part FA-PgP-12k  
  to two parts PgP-12k by weight/pGFP, (N/P: 25/1) in (A) MCF-7,  
  (B) MDA-MB-468, (C) MDA-MB-435 Wild Type, and (D) MDA- 
  MB-435 ADR cells. Groups designated with “INHIB” were co  
  Incubated with (0.33 mg/mL free folate) * P≤ 0.05, ** P≤0.01,  
  *** P≤0.001, **** P≤0.0001 ..................................................................... 112  
 
 
 
 
 xii 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 
 5.10 Transfection efficiency of PgP-12k/pGFP, FA-PgP-12k/pGFP and  
  mixed micelles comprised of one part FA-PgP-12k to two parts  
  PgP-12k by weight/pGFP (N/P: 25/1) complexes in (A) MCF-7  
  (B) MDA-MB-468 (C) MDA-MB-435 wild type (D) MDA-MB-435 
Doxorubicin resistant variant. * P≤ 0.05, ** P≤0.01, *** P≤0.001,  
  **** P≤0.0001 vs control. * P≤ 0.05, ** P≤0.01, *** P≤0.001,  
  **** P≤0.0001 vs FA-PgP-12k ................................................................. 113 
 
 5.11 Transfection efficiency of FA-PgP-12k/pGFP and mixed micelles  
  comprised of one part FA-PgP-12k to two parts PgP-12k by  
  weight/pGFP (N/P: 25/1) complexes in (A) MCF-7 (B) MDA-MB- 
  468 (C) MDA-MB-435 wild type (D) MDA-MB-435 Doxorubicin  
  resistant variant. Groups designated with “INHIB” were co incubated  
  with (0.33 mg/mL free folate). * : P<0.01 * P≤ 0.05, ** P≤0.01,  
  *** P≤0.001, **** P≤0.0001 vs FA-PgP-12k, * P≤ 0.05, ** P≤0.01,  
  *** P≤0.001, **** P≤0.0001 vs FA-PgP-12k Mix mixed micelles  
  comprised of one part FA-PgP-12k to two parts PgP-12k by weight ........ 115 
 
 5.12 Intracellular trafficking of Rhodamine-PgP-12k/FA-PgP-12k/pGFP 
complexes in MDA-MB-435 wild type cells a) 24 hours and b) 48  
  hours post transfection ............................................................................... 118  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 
 5.13 Cytotoxicity of Doxorubicin HCl, FA-PgP-12k and mixed micelles  
  comprised of one part FA-PgP-12k to two parts PgP-12k by weight,  
  FA-PgP-12k and mixed micelles comprised of one part FA-PgP to  
  two parts PgP-12k by weight/pGFP complexes, DXR (Figure 5.13  
  caption, continued) loaded FA-PgP and Doxorubicin loaded mixed  
  micelles comprised of one part FA-PgP-12k to two parts PgP-12k by  
  weight, Doxorubicin loaded FA-PgP-12k and Doxorubicin loaded mixed 
micelles comprised of one part FA-PgP-12k to two parts PgP-12k by 
weight/pGFP complexes in (A) MCF-7, (B) MDA-MB-435 Wild Type,  
  and (C) MDA-MB-435 ADR cells (top row to bottom row respectively). 
Concentration of Doxorubicin HCl used was equivalent to amount of 
Doxorubicin used in DOX loaded PgP groups. PgP/pGFP complexes  
  were formed at N/P 25/1 and both PgP alone and PgP/pGFP complexes  
  were diluted down to concentration of PgP found in designated N/P 
equivalent. * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 vs  
  control, * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 vs  
  equivalent PgP or PgP/pGFP group, éP≤ 0.05, éé P≤0.01, ééé  
  P≤0.001, éééé P≤0.0001 vs equivalent DOX HCl dose ...................... 120 
 
 5.14 Cell uptake of siGLO/FA-PgP-12k and of one part FA-PgP-12k to two  
  parts PgP-12k by weight (N/P: 25/1) complexes in MDA-MB-435 ADR  
  cells 4 and 24 hours post transfection. Groups designated with “INHIB”  
  were co incubated with (0.33 mg/mL free folate). (A)% uptake (B) mean 
fluorescence value (F). * P≤ 0.05, ** P≤0.01, *** P≤0.001,  
  **** P≤0.0001 vs FA-PgP-12k MIX, P<0.01 * P≤ 0.05, ** P≤0.01, *** 
P≤0.001, **** P≤0.0001 vs FA-PgP-12k .................................................. 122 
 
 5.15 Metabolic activity in MDA-MB-435 ADR cells after knockdown with 
ABCB1 targeted or scrambled siRNA polyplexes. RNAiMAX, PEI,  
  PgP-12k, or FA-PgP-12k/siRNA (N/P) polyplexes with and without  
  50 µg/mL DOX treatment .......................................................................... 123 
 
 
1 
CHAPTER I 
 
INTRODUCTION 
 
 
What is Cancer? 
Breast cancer remains a leading cause of death worldwide. 1 It accounts for 22.9% of 
cancer occurrences and 14% of all cancer related deaths in females internationally. 2 A 
tumor is the result of the accumulation in cellular genetic defects resulting the unchecked 
proliferation of cells. 3 The presence of a variety of biological barriers hinders effective 
therapeutic delivery and contributes to unintended side effects. Tumor populations are 
often heterogeneous, resulting in the development of drug resistance sub-populations 
during treatment; ultimately resulting in the failure of the clinical intervention.4 
 
Tumor genetics and heterogeneity 
Cancer is a cell population that has accumulated a variety of genetic alterations and has 
lost the ability to be fully regulated by the host. Tumor progression is multistage and 
involves a variety of genetic factors and mutations that can ultimately result in the 
tumor’s migration into the blood stream and the subsequent deposition and growth of 
secondary tumors (metastasis) 5. Metastasized cancers are late stage and often terminal. 
Tumor cells that have gained the ability to form new anchorage sites and undergo virulent 
proliferation belong to a classification of cell types termed cancer stem cells (CSC’s). 
Late stage tumors possess heterogeneous populations of cells, which can be then further 
subdivided into either into stem cell-like populations, or non-stem cell like populations.  5 
CSC’s often possess a resistance to both chemo and radiotherapies exacerbating 
 2 
eradication. 6 Therapeutic success requires the elimination of all tumorigenic populations 
within the host to ensure no nucleation points in the body exist to break remission. 
Originating from host’s native tissue, cancer is able to evade detection by the immune 
system due to its intrinsic similarities. Given enough time, this mass will continue to 
collect genetic mutations, and eventually metastasize through the bloodstream or lymph 
system, and proliferate throughout the body. 3 There often are common motifs between 
each type of cancer but ultimately each case is uniquely dependent on the host and its 
history; necessitating customizable treatment options to ensure therapeutic success. 
 
Current Treatments 
While radiation and surgery remain excellent short-term options, often-residual cell 
populations remain post treatment, which subsequently proliferate and result in tumor 
recurrence. Often these treatments are done in concert to maximize effectiveness.7 
 
Surgical removal 
Typically, breast cancer is removed surgically with either a mastectomy (full breast 
removal) or with a lumpectomy (partial breast removal). The removal of the effected and 
surrounding tissues is meant to ensure the removal of tumor cells to halt proliferation via 
physical extraction. Partial breast removal is usually accompanied by a radiation regimen, 
which destroys the components essential to cellular division.7 
 
Radiation can be applied immediately after the surgical removal or in daily doses over the 
course of five weeks following lumpectomy. In the 5-week course treatment, radiation is 
applied every day across the entire breast with a booster dose being applied at the end of 
 3 
the course. While excessive damage is avoided to the best of the medical staff’s ability, 
this method aims to irradiate all cancerous cells, often at the cost local healthy tissue 
damage.7 
 
Chemotherapies 
Chemotherapy is the introduction of chemical agents that are designed to slow the rapid 
growth of cancer. This type of treatment has contributed a 24% decrease in breast cancer 
related deaths between the years 1990 and 2000. 8 However, the nonspecific nature of 
chemotherapy often has detrimental effects upon the patient, often resulting in nausea, 
weight loss, loss of hair and loss of energy; making it a less-than-ideal treatment 
compared to a targeted therapy with a similar anti-tumorigenic efficacy.8 
 
Chemotherapeutics are systemic treatments, which aim to halt tumor growth and cancer 
colonization throughout the body. Current drugs include: vinblastine, vincristine, 
daunorubicin, docetaxel, doxorubicin, and paclitaxel, of which many exhibit solubility 
problems in aqueous environments. 9  
 
The mechanisms of these drugs vary and their delivery is untargeted, often inadvertently 
effecting healthy populations of rapidly proliferating cells across the entire body. 
Encapsulation of chemotherapeutics within a drug delivery vehicle (DDV) can assist in 
increasing drug solubility and mitigating systemic toxicity. Economic considerations of 
DDVs generally require at least 10% loading by weight and sterilization via 0.22-micron 
filtration is preferred. 10  
 
 4 
Unfortunately, chemotherapeutic intervention is often insufficient and can result in the 
development of drug resistant tumors via colonial microevolution. 11     
 
Drug Resistance and its Challenges 
Development of Multiple Drug Resistance in cancer 
Cells have the native ability to remove broad classes of hydrophobic drugs via P-
glycoprotein (P-gp) pumps.  12 The P-glycoprotein is a 170 kD protein in the ABC 
cassette binding protein family, which contains nine other members that have been linked 
to chemoresistance. 9 Encoded by the multidrug resistance gene (ABCB1), this protein 
functions in the broad removal of toxins from the lipid bilayer.  4 Once chemotherapy has 
begun, cells with low levels of P-gp begin die; leaving a greater proportion of resources 
for the surviving populations to utilize in proliferation. 9 This process selects for, and 
yields populations of cells with overexpressed levels of P-gp pumps. Overtime, these 
populations proliferate and result in a mass of cells that possess elevated quantities of 
ABC products and are unresponsive to chemotherapeutic treatment. 4 There are additional 
factors that contribute to drug resistant phenotypes: multidrug resistant protein (MRP) 
upregulation, p53 downregulation and BCL-2 alteration have all been cited to desensitize 
cancer to chemotherapeutic treatment through a variety of mechanisms. Minimization of 
P-gp levels or restoration of endogenous MRP, P53, BCL-2 gene activity could 
contribute towards the elimination of drug resistant phenotypes. 3,13 
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Gene Therapy 
Gene therapy is the alteration in the production or activation of a specific protein to 
change levels to desired quantities. This process often entails the excision and 
replacement of a malfunctioning gene with the correct version of DNA, placement of 
translatable copies of DNA within proximity of nuclear machinery, or interference with 
protein production. To accomplish any of these goals, a DDV must traffic the correct 
sequence to the intended cellular target. This can be accomplished in many different ways 
but can be divided generally into viral and non-viral modalities.14 
 
Viral vectors 
Viral insertions capitalize on the intrinsically efficient DNA insertion methods that are 
native to viruses. The replacement DNA is loaded into a viral capsule and released into 
the body to perform gene excision and substitution, a process termed transduction. 
Viruses have a limitation to the size of their genetic construct, Adeno-associated virus 
capacities can be as small as 5.2 kB, limiting their flexibility to deliver more complex 
sequences. 15 A major drawback to this approach is the result of the non-specific nature of 
attack virus’s use in their lifecycle, which could result in unintended gene replacements 
in healthy cells. Furthermore, viruses can induce an immune response due to their 
morphological similarities with their natural counterparts, which could ultimately result 
in the therapy becoming less effective with time or induce anaphylactic shock adding a 
potential life threatening allergic response. Despite its shortcomings, this type of 
approach is still heavily pursued as a treatment option because of the more permanent 
methodology of gene replacement relative to non-viral vectors.14 
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Non-Viral vectors 
Non-viral methods include the use of either DNA or siRNA to either increase or decrease 
production of a desired protein. DNA is introduced into the cell via endocytic processes 
and can encounter the nucleus where it is transcribed into mRNA and eventually the 
protein of interest. siRNAs can be introduced in a similar manner but need only to 
migrate to the cytosol to induce the destruction of mRNA.  
 
siRNA 
siRNA are short RNA segments that can be introduced into the cell environment, where 
they then interfere with the production of proteins, through a process termed knockdown. 
siRNA molecules function by harnessing one of the cell’s endogenous mRNA control 
pathways, the RNA-induced silencing complex (RISC). 16,17 This protein complex forms 
from the uptake and incorporation of siRNA into the protein components of the RISC and 
forms a sequence specific nuclease that finds and cleaves complementary sequences of 
mRNA. This complex reduces the levels of mRNA transcript available within the cell; 
resulting in a reduction of protein translated. Naked siRNA delivery often results in 
unacceptable efficiency and/or off target effects, resulting in inadequate protein reduction 
or reduction of non-target proteins respectively. Complexation with a positively charged 
polymer segments within a targeted DDV has been shown to increase efficacy and 
specificity of knockdown treatments.16,17 
 
The cleaved messengers can no longer pass on their message to a ribosome, and reduce 
the oncogene’s expression within the cell. 14 This method can be exploited to halt 
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proliferation of cancer cells entirely or enough to allow for other methods to eliminate all 
traces of the cancer from the body. Much like viral based methodologies there are 
inherent problems with the treatment’s efficaciousness and specificity. The cellular 
uptake of DNA is often low. 18 Absorption rates are hindered because of the negative 
charge of the nucleic acids electrostatically repelling the negative charges contained 
within the cell membrane. In the DNA’s case, the relatively larger size of DNA further 
inhibits uptake. The body also contains DNase/RNase, enzymes that destroy nucleic 
acids, further exacerbating delivery issues of nucleic acids. 18  
 
The utilization of nanoparticles as vessels to house either DNA or siRNA for delivery is a 
promising venture. Nanoparticles are simply any small particles between the sizes of 1-
100 nanometers. 19 The particle itself can be made from a variety of materials ranging 
anywhere from lipids to polymers. The ideal vessel has protective properties for the 
fragile DNA and even more fragile siRNA. The vessel must be biodegradable and non-
toxic, to not poison or harm the cell or body during travel or delivery. The vessel must be 
conducive to cellular uptake via endocytosis. Nanoparticles that are marked for use with 
DNA must also perform condensation of nucleic chains into a manageable size for 
intracellular import. 18 The loading of nucleic acids into nanoparticles has exhibited 
marked improvements in delivery effectiveness over their naked counterparts. 
 
In a review of polymeric micelle delivery systems by Jhaveri and Torchillin, eight 
criterion were identified as necessary for a drug delivery vehicles’ success in delivering 
genetic therapeutics, the vector must: 1) not exhibit toxic or immunogenic qualities to 
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evade acute patient reactions, 2) compact nucleic agents, 3) shield itself and its cargo 
from nuclease activity, 4) elude recognition from the immune system, 5) be over 50 nm 
but under 500nm to evade renal clearance and reticuloendothelial system recognition 
respectively, 6) avoid aggregation with serum proteins and uptake by unintended cellular 
targets, 7) traverse the blood supply to target tissue and undergo endocytosis to the 
correct subcellular compartment for 8) adequate release of therapeutic in cell cytosol to 
induce therapeutic response.  20-22 While originally contextualized to siRNA delivery, it is 
obvious that such characteristics are necessary for success of any multifunctional drug 
delivery system regardless of the mechanism of action.22 
 
Polymeric Micelles 
Polymeric micelles are a subcategory of nanoparticle-based DDV’s that have the 
potential to fulfill all requirements of a successful multifunctional vector. Micellization is 
thought to be a byproduct of the hydrophobic effect, a phenomena that is resultant of the 
free energy associated with the total rotational and translational activities between each 
individual molecule. 23 Self-assembly into ordered aggregates is a result of the relatively 
increased amount of energy required for water molecules to form a clathrate-like change 
around the lipophilic moiety compared to the energy required to form aggregates with 
hydrophobic chains sequestered in a central reservoir. At a certain concentration of 
micelle (CMC) above a certain temperature  (Krafft temperature or critical micelle 
temperature [CMT]), unimer aggregation occurs. The long-range order is determined by 
the relative size between hydrophilic and hydrophobic domains in solution or the 
Hydrophilic Lipophilic Balance (HLB). HLB is defined by the hydrophilic molecular 
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weight relative to the molecular weight of the whole molecule multiplied by 20. HLB’s 
range from 0-20, with values below 10 representing hydrophobic dominant substances 
with larger numbers representing hydrophilic dominant substances.  
 
The importance in hydrogen bonding, specifically with amphiphiles in water, help 
illustrate micelle dynamics are ultimately limited by aggregate energetic properties 
associated with the hydrophilic/hydrophobic domain size.24  As a result of the same 
thermodynamic principles, long range order progresses from micelles, with lipid tails 
being sequestered in spheres with no long range order, to micelle-cubic, a similar 
aggregate structure whose interactions induce a long range order of randomly distributed 
aggregates. This balance also has an effect on the morphology of the individual micelle, 
as proportion of hydrophobic block increases in a particular system, polymeric micelles 
will follow a progression through different morphologies: star-like, intermediate, and 
crew-cut micelles. In star-like micelles, the size of hydrophilic blocks greatly exceed 
hydrophobic blocks, aggregation will be sterically hindered by the hydrodynamic volume 
of the hydrophilic moiety. If HLB is similar, packing limitations are still limited by 
increased hydrophilic volume, as hydrophobic block length increases beyond this point 
micelles will be limited by the flexibility between associated hydrophobic chains.25 
 
As concentrations of amphiphile continues to increases and/or as the hydrophobic portion 
relatively increases, hydrophobic forces begin to dominate and form cylindrical tubes 
arranged along a hexagonal lattice, with continued increases these tubes will form an 
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intermediate tube network on their way to a lamellar conformation before finally 
dropping out of solution beyond the cloud point. 
 
Many polymeric micelle systems have been shown to evolve in two discreet steps and 
relaxations. 26 First is the phase transition from aligned surface unimers nucleating and 
forming the lowest energy aggregates, a process that continues until an individual chain 
insertion would increase the overall free energy of the system. A second slower process 
involves individual unimer condensation and expulsion or whole micelle merger and 
fission. 24 The speed and liquidity of unimer exchanges between micelles and free chains 
are retarded by increasing hydrophobic block length or number, such an effect may slow 
kinetic exchange to such a degree that, the micelle population may not exhibit any 
observable changes over course of the experiment. In such conditions, polymers are 
considered kinetically frozen during experimental timeframes. 25  
 
Overtime, these systems evolve to the greatest amount of entropy but the transition 
timescale and final conformation of aggregates is dependent on synthetic composition, 
initial formation conditions, temperature, pH, protein and salt contents. 25 Micelle 
populations can be described by size distribution curves that characterize the minimum 
and maximum size of aggregates. 27 Polymer composition is an important factor in 
micelle dynamics, increasing hydrophobic block length and number has been shown to 
decrease kinetic exchange. 26 If experiments are contingent upon reaction kinetics in any 
way, experimental timescale may also introduce inadvertent complications in determining 
underlying factors in DDV performance.  
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Morphological characteristics of polymeric DDV’s have been shown to have a profound 
impact on performance and are intimately tied to concentration and alteration of 
microenvironment. Applying traditional drug analytical methodologies, such as dose-
response curves, may overlook multiple confounding variables because of morphological 
differences that are resultant of variation of dose. Increasing polymer concentration may 
have an effect on morphology of aggregates, which may result in effects that run 
countercurrent to perceived effect of the elevated dose. In other words, investigations of 
polymeric system behavior requires coupled experiments that isolate the differences in 
form as a result of dose in order to accurately determine the dominating factors in DDV 
performance. This same concept also applies to the formation of nucleic acid and 
polymeric aggregates or polyplexes.  
 
Formation of polyplex 
Limitations of polyplex size follow the same dynamics previously describe that limit 
polymeric micelle size. Polyplex formation with siRNA has also been show to take part 
in a two-step process that is reminiscent of micellization. Primary polyplexes first 
associate in a semi ordered fashion before aggregating into larger polyplexes. 
Complexation with DNA tended to be a more multilayered and sophisticated process, as 
longer DNA requires extensive folding for effective condensation. 28 Polyplex 
compositions are often described as a comparison of the average number of nitrogens per 
mole of polymer to the average number of phosphates per mole nucleic acid, or N/P ratio. 
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General Hurdles Regarding DDV 
Pathway to tumor 
Angiogenesis is a hallmark of advanced cancers.  21 Tumors can no longer receive 
adequate nutrition via diffusion after growing 1-2 mm3 and require access to a blood 
supply. 29 Tumors recruit nearby vasculature to supply them with the required elements 
for survival. As the vessel is often recruited in a primitive way, the native intracellular 
junctions are poorly developed.  21,30 This architecture leads to passive size-dependent 
absorption of nanoparticles, via a process termed the Enhanced Permeation Retention 
(EPR) effect. 31 DDV’s will passively diffuse as a result of the pressure differential 
between blood vessels and the tumor’s interstitial environment, leading to enhanced 
delivery at target site relative to healthy tissues. Inadequate lymph drainage in tumor 
peripheries further encourages the nanoparticle retention 1,32  
 
Blood Circulation 
Therapeutic agents must maintain stability in the blood stream in order to reach the 
target. The agent must be able to circulate in the blood for a least a short period of time 
without removal by endogenous macrophages, suffering chemical degradation, forming 
complexes with native blood borne proteins, or inciting non-specific immunogenic 
reactions. In order to contend with circulation time issues, surface modifications have 
been formulated that assist in the evasion of immunogenic or reticuloendothelial 
detection and removal. Polymers such as Polyethylene Glycol (PEG) resist the binding of 
blood-borne proteins (e.g. opsonin) associated with macrophage removal via formation of 
a hydration shell around the complex. 32,33   
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Tumor Site Deposition 
Site deposition does not necessarily result in effective therapeutic administration. The 
dense cellular and matrix packing on the interior of tumors is a physical barrier that can 
exacerbate internal passive diffusion as a result of the elevated tumor interstitial pressure 
relative to nearby healthy tissues. 32   
 
Cellular Uptake 
The DDV must reach the correct intracellular target. This first requires the traversal of 
the cell membrane. Generally, cell membrane charge is negative due to the lacing of 
surface with proteins. Negatively charged genetic components are electrostatically 
repulsed from the membrane; positively charged systems are attracted to the membrane 
but can become electrostatically bound to membrane proteins and may require active 
trafficking to progress further into the cell. 34 Some free drugs (e.g.: Doxorubicin) can 
cross tumor cell membranes via simple diffusion, while others may require interaction 
with cellular proteins to facilitate uptake.35 
 
Given enough time, free drugs can initially cross tumor cell membranes. Often, tumors 
develop drug resistances (e.g. up regulating P-glycoprotein pump expression) 32. 
Macropinocytosis of extracellular fluid containing free drug or DDVs is another potential 
route of non-specific accumulation. In addition to simple diffusion, there are a variety of 
protein-mediated endocytosis’: clathrin-mediated, caveolae-dependent, and 
clathrin/caveolae independent endocytosis’. Each pathway is characterized by a unique 
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set of proteins, trafficking modality, and vesicle size. Pathway determination is often 
associated with DDV size. 36 
 
There has been a lot focus on the utilization of active transport to facilitate the uptake of 
delivery particles. Cancers can over-express receptors that are sensitive to specific 
molecules. Folate, biotin, galactose, and hyaluronan are examples of targeting moieties 
that have been identified as potential candidates for assisting uptake of DDV molecules 
in cancerous tissues. 37 There is an established body of work exhibiting the efficacy of 
utilizing active transport as a means of overcoming drug resistant cancers.  13 There are 
also more generalized means of uptake involving the protein complexes Clathrin and 
Caveolin. Clathrin complexes form when certain receptors, such as transferrin or low-
density lipoprotein receptors, are bound. This activates a cascade in which a protein coat 
forms and pulls in part of the membrane forming a vesicle that fuses with early 
endosomes and ultimately follows the lysosomal degradation pathway.  
 
Caveolae-initiated complexes play a more sophisticated role in the cell as they involve 
some signaling functionalities as well as transport duties. Caveolin-1 acts as the catalyst 
for the formation of the caveolae vesicle, which uniquely fuses with either a 
multivesicular body or a cavesome, both of which have neutral pH (however, fusion with 
the endosome occasionally still occurs). 38 This neutral pH state is important to many 
DDV’s as reduced lysosomal pH often results in the degradation of some drug and 
nucleic acid based therapies. A number of Caveolin focused nanoparticles have been 
created including a polymeric cross-linked poly(ethylene oxide)-b-poly(methacrylic acid) 
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micelle as well as the construction of Aminopeptidase P (APP) monoclonal antibodies to 
target the APP rich caveolae. 38 Caveolae- mediated endocytosis functionality is 
important as it has the possibility of evading the endosome-lysosome pathway, a common 
site of genetic component deterioration. 
 
Prepared complexes exist across a range of sizes and charges that variably alter over 
time. This variation may have a critical impact on cellular uptake distributions.  36 
Furthermore, due to the heterogeneity of trafficking mechanisms across cells it is very 
likely that optimal parameters are cell specific and caution must be taken in the 
generalization of results.39 
 
Intracellular Pitfalls 
Therapeutics encapsulated within the DDV complex must be taken up by cell and escape 
destructive processing pathways. Failure to bypass the late endosome will result in 
degradation via peroxidase, lysozyme and low pH. 16 Utilization of polymers with 
primary and secondary amines such as branched polyethylenimine (PEI) can promote 
early endosome escape via the “proton sponge” effect. 40 The protonation of primary and 
secondary amines as pH drops in the endosome provides a buffering effect that results in 
the influx of protons, counter-ions, and water. This influx of molecules causes swelling of 
the endosome and results in the rupture and release of contents into the cytosol.41 
 
This mechanism is still contentious and an alternative hypothesis has been proposed that 
suggests that PEI facilitates escape via membrane interactions into the cytosol. 42 Once in 
the cytosol, it is unclear as to whether the positive charge of a protonated PEI promotes 
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attraction between its cargo and the proteins in the intracellular space including the 
nucleus (providing potentially increased nuclear localization) and at which point or by 
what means the genetic cargo is released from the complex. It is clear however, that PEI 
is trafficked to the nucleus and in some cases provides adequate co-localization of 
plasmid within the nuclear machinery to ultimately result in protein expression.43 
 
Size and surface charge have a direct implication on reticuloendothelial system 
elimination rates, intracellular uptake and processing, as well as interfacial qualities such 
as the ability to bind and protect nucleic acids. 33,44 Additionally, polymer based delivery 
systems with insufficient electrostatic repulsion of units, induced by either great negative 
or positive charge, tend to aggregate and floc out of solution, rending them ineffective.45 
 
It is obvious that incorporated drug within DDV’s would have to undergo a similar 
evasion of degradation to reach their respective intracellular target. Additionally, 
incorporation of chemotherapeutics into DDV requires dissolution of complex to release 
free drug or the drug must diffuse out of the micelle core. Further DDV thermodynamic 
stability may be imbued with the addition of a hydrophobic drug (e.g. DOX), which may 
affect transgene expression levels. 46    
 
Need for Increased Specificity 
Unfortunately, no single drug has been universally applicable to all cancers. Therefore, 
targeted therapies were designed to further mediate specific delivery and promote cell 
internalization in a cancer-specific fashion, as a way to decrease unintended effects on 
healthy cell populations. The addition of a targeting ligand has been long sought as an 
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answer to specificity problems. However, because of the similar genetic profile cancer 
shares with its host, the existence of a cancer-exclusive moiety has yet to be discovered. 
Fortunately, there are a plethora of overexpressed moieties and transporters that are 
associated with common cancer types, of which many can easily be conjugated to 
polymeric micelles.  
 
Ultimate goal of any chemical based interventions is to accumulate enough of agent in 
target population to induce the desired effect with minimal damage to the host’s healthy 
cell populations. 
 
Receptor Targeting 
Because of their selective up regulation in some cancers and relative absence in normal 
tissue; surface proteins such as Human Epidermal Factor-2 (HER-2), prolactin, and folate 
receptors have been utilized as a means of actively transporting DDV’s into cells.  47    
 
HER-2 
Human epidermal growth factor number 2-receptor tyrosine kinase (HER2/Neu, Her2 or 
ErbB-2) is a growth receptor that simulates rapid proliferation via inhibition of PI3K/Akt 
apoptotic pathway. 48 This anti-apoptotic pathway is in excess within cells over 
expressing Her2, increasing levels of proliferation; resulting in tumors with bigger sizes 
and higher growth and metastatic rates. The more aggressive nature of the Her2 positive 
tumor is correlated with reduced survival rates. 8 Many treatments focus on the inhibition 
of this pathway in an effort to quell tumor aggression via competitive inhibition. 49 Her2 
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overexpression provides an advantage in selectivity but does not address subsequent 
intracellular uptake and processing barriers faced by DDV’s.  
 
The Her2 receptor is considered over expressed in 25-30% of breast cancers of all types, 
with an increased rate of expression found in malignant tumors. 50 The Her2 protein 
receptor is the activator of the “survival” pathway because of its assistance in regulating 
cell proliferation via apoptotic inhibition. 48 The research undertaken because of the high 
rates of mortality related to this subsection of cancer has resulted in the FDA approved 
Trastuzumab (name brand Herceptin).  
 
Herceptin is a humanized monoclonal recombinant antibody that selectively binds to the 
extracellular side of Her2. This drug has had considerable levels of clinical success 
exhibiting increased levels of disease free survival. 51 In one study, the addition of 
Herceptin to chemotherapy resulted in a 33% decrease in mortality after 3 years. 8 The 
side effects of Herceptin are much less pronounced relative to more traditional therapies, 
most likely the result of higher levels of specificity as well as the non-lethal mechanism 
of the drug upon the cell. 52 This reduction of side effects makes Herceptin and drugs like 
it an improvement over traditional treatments of cancer.  
 
In another system, a nanoparticle was utilized to co-deliver Herceptin and Paclitaxel, a 
mitotic spindle inhibitor. A poly {(N-methyldietheneamine sebacate)-co-[(cholesteryl 
oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate} 
nanoparticle was loaded with both drugs. The complex was found to have high levels of 
anticancer effects, greater than each treatment alone. The ability to co-deliver drugs is 
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another advantage associated with the use of nanoparticles. Drugs delivered at the same 
time can work more synergistically than can drugs applied at different times, improving 
treatment effectiveness.53 
 
Herceptin was also conjugated to dextran iron oxide nanoparticles. The vehicle was 
designed to mark Her2 positive tumors and create greater contrast to their surroundings in 
magnetic resonance imaging (MRI). When applied to mice with Her2 positive tumors, 
there was a 45% enhancement drop of the imaging, indicating a high accumulation 
nanoparticles in the vicinity of the tumor site. 54 This significant increase in enhancement 
still occurred despite the endogenous low-level presence of the Her2 receptor in normal 
cells. The presence of Her2 is found to be around 100 times more prevalent in Her2 
positive tumors when compared to Her2 negative tumors. 52 The two orders in magnitude 
difference in the exhibition of Her2 receptors can be capitalized upon in antibody-
targeted gene therapy. 
 
Prolactin Receptor Overexpression 
The prolactin receptor is a protein that is found in more than half of breast cancer 
incidences and has been found to be frequently over-expressed in late stage cancers. 
Over-expression, again, is correlated with an overall reduction in host survivability 
partially due to increased incidence of metastasis. The activation of the prolactin receptor 
can lead to further activation of Jak2/Stat5 and Jak1/Stat3 signal cascades, which will 
ultimately lead to increased amounts of cellular growth, division, and survival. 55 In 
addition to this main pathway, prolactin receptor activation also leads to activity in the 
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Ras/Raf/MAP kinase pathway as well as protein kinase C activation, which further 
promotes cell longevity.56 
   
There have been a number of prolactin analogues developed in order to exploit the 
therapeutic possibilities involving the antagonization of the prolactin receptor. Noticeable 
success has been found in the G129R protein. 56 This protein replaces the glycine at 
position 129 in prolactin with an arginine and provides for competitive inhibition of the 
prolactin receptor; ultimately resulting in an apoptotic-inducing down regulation of BCL-
2 and upregulation of TGF-B.57 
 
While still in the beginning stages of research, use of prolactin as a stem-cell conversion 
agent is currently underway. Prolactin natively regulates formation and proliferation of 
mature breast tissue, indicative of stem cell activity; which suggests potential for other 
stem cell interactions. 58 There has been suggestion that prolactin antagonism alters stem 
cell population proportions via alteration of the Stat5 pathway in prostate cancer. This 
increases the promise that a prolactin antagonist could alter stem populations in other 
prolactin-expressing cancer types. 59 Furthermore, the creators of the G129R protein have 
filed for a patent that indicates reduced stem cell population proportions as a result of the 
administration prolactin in breast cancer. 60 Despite current gaps in prolactin-antagonist-
related breast cancer stem cell conversion research there is good foundation to utilize the 
complex as part of a novel multifunctional drug delivery system. 
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Folate 
Some cancers possess unregulated extracellular receptors that are relatively absent in 
normal tissue; folate receptor alpha is an exemplar protein and has been frequently 
utilized as a means of selectively transporting DDV’s into cells. 47 Folate is an essential 
cofactor to DNA replication and is needed in large quantities by rapidly dividing cancer 
masses. Elevated levels of folate receptor (up to 100x expression) are correlated with 
aggressive cancers in the brain (75% of cases), ovaries (90%), lung (37%) and breast 
(32%).61,62 Breast cancers positive for folate receptor alpha overexpression (FA+) are 
associated with grim outcomes. 63 Furthermore, triple negative breast cancers, or cancers 
without elevated levels of estrogen, progesterone, or HER-2, represent a cohort of breast 
cancers that lack defined targeted therapeutic approach and have been also noted to have 
(FA+) in over 80% of cases. 64-66  
Cell	line	 Tissue	
Type	
Estrogen	
Receptor	
		
Progesterone	
Receptor		
Human	
Epidermal	
Factor-2		
Folate	
Receptor	
Alpha		
MCF-7	 Luminal-like	adenocarcinoma	 +	 +	 -	 +	
MDA-MB-
468	
	
Basal-like	adenocarcinoma	 -	 -	 -	 -	
MDA-MB-
435	 Wild	
Type	
Ductile	Carcinoma	(post-EMT)	 -	 -	 -	 +	
MDA-MB-
435	
Doxorubicin	
resistant	
variant	
Ductile	Carcinoma	(post-EMT)	 -	 -	 -	 +	
Figure 1.1: Descriptions of cell lines. Estrogen receptor, Progesterone receptor, Human 
Epidermal Factor-2 absences together represent cell lines that are triple negative breast 
cancers. 67-70 
 
 22 
Fortunately, both alpha and beta folate receptors (~38 kDa) exhibit limited distribution in 
normal tissues. 61 This level of upregulation and relative tissue specificity compounded 
with the great binding affinity of folate (Kd = 10-10 M), makes folate an attractive ligand 
to add targeting functionality to DDV’s. 67 There is little difference in the mechanism by 
which free folate and folate-conjugated particles are trafficked. Free folate (and folate 
conjugated particles) initiates active transport into cell and is moved along the endosomal 
pathway; thus allowing DDV’s containing branched PEI to escape endosomal 
degradation via the proton sponge effect. 47,67 
  
Need for a Multifunctional DDV 
Over the pasts few decades three subsequent generations of non-viral delivery vectors 
have been engineered to address the shortcomings of previous technologies and 
incorporate lessons learned from a continuously evolving understanding of the delivery 
challenges associated with drug resistant breast cancer. 71 Initially relying solely on 
passive diffusion via the EPR effect, it became clear that further modification would be 
required to sufficiently increase intracellular accumulation. 72 This addition of active 
targeting via antibody or small molecule ligands improved the specificity of DDVs, but 
still left much to be desired in therapeutic efficacy. 73 It is currently recognized that a 
multifunctional drug delivery system that interacts with the target in a combinatorial way, 
i.e. co-delivery of a variety of genetic therapeutics and conventional pharmacological 
agents is necessary to address the complexities of breast cancer treatment in an effective 
manner. 1, 13  
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CHAPTER TWO 
RESEARCH OBJECTIVES 
 
Project Rationale 
Despite the recognition that simplicity often yields the most commercially viable product, 
increasingly complex molecules have been pursued in an effort to address the 
multidimensional challenge of breast cancer. 81 These products, while successfully 
increasing their therapeutic viability, fail to recognize the clinical realities related to 
dosing, administration and product storage. 82,83 It has been recognized that drug loaded 
(PLGA)-b-PEI/pDNA lyophilizable systems can be easily reconstituted for use and 
possess extended shelf life over their contemporaries.5,6 However, previously investigated 
iterations utilizing two 36kD PLGA blocks exhibit transfection efficiencies that leave 
much to be desired despite a high degree of drug loading.5,6 Low levels of transfection 
lead to this investigation of the utilization of smaller PLGA blocks in a similar capacity, 
in an effort to find a balance between drug loading and nucleic acid delivery capabilities. 
PLGA weights were chosen to investigate the effect of HLB on transfection efficacy and 
drug loading in the context of a multifunctional drug delivery vehicle.   
 
Proposed is a unique combination of the amphiphilic copolymer, poly  (lactic-co-
glycolic) acid-g-polyethylenimine) (PgP) micelle delivery system as a flexible platform 
technology. PgP theoretically has potential advantages as a delivery system: 1) it should 
maintain some degree of morphological regularity as a result of associated 
thermodynamic forces, potentially limiting primary amine exposure via steric hindrance 
 24 
reducing DDV toxicity 2) its hydrophobic core can serve as a reservoir for hydrophobic 
anticancer drugs 3) its positively charged PEI hydrophilic shell could be used for 
complexation with negatively charged nucleic acids (therapeutic plasmid DNA or 
siRNA) which may further reduce primary amine exposure and DDV toxicity, and  4) 
targeting moieties can be easily conjugated on the surface of micelle. 84,85 All components 
have ideal chemistries for controlled synthesis with each other and combination with 
targeting antibodies or other small molecules.  
 
Doxorubicin (DOX) is a commonly used chemotherapeutic drug that functions via 
Topoisomerase II inhibition, intercalating DNA and impeding proper translation. DOX is 
often associated with unwanted cardiotoxicity. 95,96 DOX exhibits poor aqueous 
solubility. 97  Doxil, a PEGalayed liposomal version of DOX that was approved by the 
FDA for treatment of Kaposi’s sarcoma, ovarian cancer and multiple myeloma has show 
to reduce DOX-associated cardiotoxicity and increased circulation times.98 DOX exhibits 
absorbance at 480nm and has a ~200nm bandwidth, both of which can be visualized and 
quantified with microscopy and flow cytometry.99 DOX’s extensive use, hydrophobicity, 
and optical properties make it an ideal candidate for use as a model for incorporating 
chemotherapeutics into PgP.  
 
The addition of folate moiety (FA-PgP) should increase specificity of DDV, resulting in 
fewer systemic side effects and help establish a standard protocol pertaining to the 
incorporation of therapeutically relevant targeting moieties to PgP’s structure. Delivering 
ABCB1 targeted siRNA by complexing with PgP should reduce drug efflux pump 
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quantity and assist in the mitigation of drug resistance. Doxorubicin loaded FA-
PgP/siABCB1 complexes will be a potential targeted therapeutic intervention developed 
from PgP designed to overcome drug resistant breast cancer more safely and substantially 
improve the length and quality of life of cancer victims. Success of this pilot study 
illustrates a potential scheme of PgP constructs that can deliver multidrug, multigene-
targeted cocktails. 100 
 
Altogether, this suggests that a variety of therapeutically relevant PgP target/gene/drug 
configurations merit investigation. The development of PgP as a lyophilizable system 
will begin to address shelf life and production issues while maintaining the standard 
chemotherapeutic format, accomplished by DDV reconstitution and subsequent 
administration via intravenous injection. Development of this system could strike a 
balance between the realities of medicine today with the potential of the personalized 
treatments of tomorrow. This incorporation of genetic and targeting technologies in a 
product that in a familiar format to practitioners could ease the transition, adoption and 
incorporation of nanotheraputic drug delivery vehicles into the clinical workspace. 
 
Specific Aims 
Aim 1: Synthesize and characterize poly (lactide-co-glycolide) -graft-polyethylenimine 
(PgP) as nucleic acid carrier 
Approach: Poly(lactide-co-glycolide) (PLGA) of a various molecular weights 
will be conjugated to branched polyethylenimine (PEI, 25kDa) yielding poly 
(lactide-co-glycolide) -graft-polyethylenimine) to characterize the effects of 
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PLGA length on nucleic acid delivery and DDV toxicity. Polymer structure and 
physicochemical properties will be investigated using 1H-NMR, GPC, DLS, 
various gel based assays, hemolytic and hemoaggregation assays. Utilizing a 
panel of breast cancers (MCF-7, MDA-MB-468, MDA-MB-435 wild type and a 
Doxorubicin resistant variant), transfection efficacy will be assessed by using 
pGFP as a reporter gene while cytotoxicity of DDV will be assessed via MTT 
assays.  
 
Aim 2: Evaluate poly (lactide-co-glycolide) -graft-polyethylenimine (PgP) as a drug 
carrier 
Approach: DOX-loaded PgP and DOX-loaded PgP/pGFP particles will be 
prepared, characterized, and tested against panel of breast cancers to determine 
the additional cytotoxicity of DDV imbued by the loading of DOX.  Data 
acquired in aims 1 and 2 will be used to screen PgP weights for overall viability 
as a multifunctional drug delivery vehicle. The best candidate will be synthesized 
with a folate-targeting moiety undergo further testing. 
 
Aim 3: Synthesize and characterize folate functionalized poly (lactide-co-glycolide) -
graft-polyethylenimine nanoparticles (FA-PgP) as drug and siRNA carrier for 
combinatorial therapy for the efficient treatment of various types of breast cancer cells in 
vitro.  
Approach: Folate will be conjugated to PEI portion of the most viable PgP 
format using a PEG spacer to illustrate the effect on DDV physicochemical 
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properties, pGFP plasmid delivery, and DOX loading capabilities. Doxorubicin 
loaded FA-PgP and Doxorubicin loaded FA-PgP/pGFP particles will be prepared 
and tested to determine if complexation with pDNA at a fixed N/P ratio alters it 
toxicity relative to an equivalent amount of polymer, as size and surface charge 
have been shown to effect uptake. Finally, Doxorubicin loaded FA-PgP/ABCB1 
targeted siRNA particles will be prepared and tested against drug resistant MDA-
MB-435 ADR cells.  
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CHAPTER THREE 
SYNTHESIS AND CHARACTERIZATION POLY(LACTIDE-CO-GLYCOLIDE)-
GRAFT-POLYETHYLENIMINE (PgP) AS A NUCLEIC ACID CARRIER 
 
Introduction 
With self-assembly in mind, poly  (lactic-co-glycolic) acid-g-polyethylenimine (PgP) will 
be constructed out of hydrophobic and hydrophilic blocks. While no single polymer has 
been universally approved by the FDA for drug use there are several materials that have 
consistent track records of being a component in approved drugs, one such compound is 
Poly (Lactic-co-Glycolic) acid (PLGA). PLGA can be used as a hydrophobic core-
forming block. PLGA is a random block copolymer comprised of lactide and glycolide 
units in different ratios based on relative molar frequency. For example, 75:25 represents 
a copolymer that has 75% lactide groups and 25% glycolide group for the given 
molecular weight. Synthesis produces polymers with narrow dispersity indices cheaply, 
making them ideal for large-scale production. PLGA degrades via hydrolysis into lactic 
and glycolic acid, of which the rate is dependent upon the ratio of lactide to glycolide in 
the polymer. Generally speaking, as lactide portion increases there is a corresponding 
increase in time for hydrolytic decay. Such a quality can be used to tune time frame for 
decay. The degradation products exist in a form that is naturally produced in the body and 
should not cause localized irritation and is often cited as a polymer with ideal 
biocompatibility. 74   
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The polycationic polymer, branched polyethylenimine (bPEI) can be used as a shell-
forming block. PEI exists in a variety of lengths and morphologies ranging from linear 
units to branched units scaled from less than one to several hundred kDa. 43,75 It has been 
investigated for decades and represents the gold standard for non-viral transfection in 
terms of efficacy. 76 Despite its potential there has yet to be any significant break through 
in the translation to a commercial product due to deleterious interactions with proteins in 
the body, reducing its efficacy. Nonetheless, PEI and its many forms have been cited in 
over 100,000 papers, giving a broad base of knowledge to work from. 77   
 
Utilization of polymers with primary, secondary, and tertiary amines (1:2:1 ratio of 581 
amines [145.25:290.5:145.25]) such as branched polyethylenimine promotes early 
endosome escape via the “proton sponge” effect. 40 The presence of primary and 
secondary amines with different pKa values provides a buffering effect that results in the 
influx of protons, counter ions, and water as pH drops in the endosome resulting in the 
increase in branch repulsion as positive amines increase electrostatic repulsion and force 
the bPEI to open up much like an umbrella. This influx causes swelling of the endosome 
and results in rupture and release of nanotherapeutics into the cytosol. 41     
 
This mechanism is still contentious and an alternative hypothesis has been proposed that 
suggests that PEI facilitates escape via membrane interactions into the cytosol. 42 Once in 
the cytosol it is unclear as to whether the positive charge of a protonated PEI promotes 
attraction between its cargo and the proteins in the intracellular space including the 
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nucleus (providing potentially increased nuclear localization) or at which point or by 
what means the genetic cargo is released from the complex.  
It is clear, however, that PEI localizes at the nucleus and in some cases provides adequate 
co-localization of plasmid within the intranuclear space to result in transgene protein 
expression. 43 PEI’s use in a gene delivery context is usually defined in terms of nitrogen 
to phosphate ratios. This is a description on the number of nitrogens per mole polymer 
and the number of phosphates per mole of genetic component. This nomenclature is used 
because electrostatic complexation is a dynamic process that is influenced by the pH of 
the solution and a generalizing the number of charged moieties provides a better 
description of general polymeric behavior. 78 It has been shown that in monoculture 
settings that it ultimately is the number of uncomplexed free amines that drives both 
efficacy and cytotoxicity in a positive fashion. 77 Increased free amines, whether added as 
uncomplexed groups in a system along with complexed groupings adding up to a certain 
N/P ratio or as a homogenous system of particles, have been shown to increase efficacy 
of transgene expression. 77 These same exposed amines can cause damage to the cell by 
membrane disruption and interruption of cellular movement potentially inducing 
apoptotic or necrotic damage. 79    
 
PgP will be synthesized in a variety of weights and investigation into the 
physicochemical properties will determine if PgP-12k, PgP-25k, and PgP-50k are 
potential candidates for successful DDV platform technologies prior to moving forward 
to assess gene delivery capabilities using pGFP as a reporter gene. 
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Three different PgPs are to be synthesized with branched PEI 25kDa and three different 
molecular weights of PLGA (4kDa (lactide:glycolide 50:50), 25kDa  (lactide:glycolide 
75:25 ) and 50k (lactide:glycolide 50:50)). A designation was given to each PgP based on 
the total PLGA composition. For example, “PgP-12k” is made up of 12kDa of PLGA (3 
PLGA 4kDa:1 bPEI), “PgP-25k” has 25kDa of PLGA per molecule (1 PLGA 
25kDa:1PEI) and “PgP-50k” has 50kDa of PLGA per molecule (1 PLGA 50kDA:1PEI). 
 
Such permutations provide an investigation across block length as well as block number. 
Both parameters have implications on the kinetics of the polymer in reference to micelle 
structure. PgP is designed to increase transfection levels and reduce cytotoxicity relative 
to the current gold standard of non-viral gene therapies, branched PEI25k, in tested breast 
cancer lines. 76    
 
PgP theoretically should compact and protect its cargo from degradation, maintain a 
hydration shell to help evade immune recognition, be of correct size to capitalize on EPR 
effect, avoid renal and RES clearance, and possesses high degree of stability to allow it to 
circulate in the blood stream to reach the intended target. 86 The amine-based chemistry 
should allow for relatively easy production of base polymer system (PgP) and subsequent 
modification with a targeting moiety of interest (folate, HER-2 targeting antibody, 
etc.).47628788 Such a system could then be customized further with the pertinent genetic 
material (plasmid DNA or siRNA regulating P-gp, MCL-1, BCL-2, etc.) or hydrophobic 
pharmaceutical agents (Doxorubicin, Paclitaxel, Vincristine etc.) to imbue customized 
multifunctional capabilities to the drug delivery vector. 9,17,86,89-94 Treatment combinations 
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can be combined to co-deliver multiple genes of interest and multiple drugs to maximize 
efficacy and reduce unintended side effects. This dynamic system can potentially be used 
as an approach to a variety of ailments, not only limiting itself to the treatment of a wide 
variety of breast cancers. 
 
DDVs are often preliminarily screened through a set of standardized experiments. These 
investigations provide insight to potential sources of variation that effect delivery system 
performance especially pertaining to gene delivery- a multistep process that requires a 
precise order of intracellular events in order to transpire. It is imperative to verify 
composition post synthesis. 1H-NMR and Gel Permeation Chromatography (GPC) are 
commonly used to quantify polymeric composition.  
 
Aggregate properties such as Critical Micelle Concentration (CMC), a measure of the 
minimum concentration of amphiphile at which spontaneous aggregation is favored and a 
phase transition occurs from surface aligned free unimers to micelles, are investigated as 
a proxy for the potential longevity of blood borne complex based on the relationship with 
higher kinetic stability and lower CMC. 24 These properties dictate the size distribution of 
aggregates, which can be investigated via Dynamic Light Scattering (DLS). This same 
principle is applied to measure size dispersity differences introduced by the addition of 
nucleic acids (pDNA or siRNA). Size and surface charge have a direct implication on 
reticuloendothelial system elimination rates, intracellular uptake and processing, as well 
as interfacial qualities such as the ability to bind and protect nucleic acids. 33,44 In addition 
to providing insight to charge dynamics between gene element and polymer zeta potential 
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assessment can provide insight to the potential of aggregation via self-attraction. With the 
presence both negative and positive charge components, complexes with low zeta 
potentials run the risk of surface electrostatic repulsion being insufficient in overcoming 
attractive forces of the negative genetic moiety on surface of one complex to the positive 
polymer corona of another complex. Polymer based delivery systems with insufficient 
electrostatic repulsion of units, induced by either great negative or positive charge, tend 
to aggregate and floc out of solution, rending them ineffective. 45 Both size and 
electrostatic potential (ζ-potential) must be assessed to determine if DDV exhibits ideal 
electrostatic characteristics to avoid complex flocculation and enhance cellular uptake.  
 
Limitations of polyplex size follow the same dynamics, previously described in chapter 
one, that curb the average polymeric micelle size. Polyplex formation with siRNA has 
also been show to take part in a two-step process that is reminiscent of micellization. 
Primary polyplexes first associate in a semi-ordered fashion before aggregating into 
larger polyplexes. Complexation with DNA tends to be a more multilayered and 
sophisticated process, as longer DNA requires extensive folding for effective 
condensation.28 
 
If intravenous administration is desired, DDV interaction with the solid elements of blood 
must result in minimal hemolysis or hemoaggregation, as either of these phenomena can 
result in catastrophic patient reactions. 
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Hemolysis is a direct measure of cytotoxicity on erythrocytes, while hemoaggregation 
provides insight into the physical interactions of the delivery vehicle with solid elements 
in the blood. Both are important factors necessary to assess the safety of the delivery 
vehicle prior to in vivo evaluation.  
 
When utilizing polyionic complexes it is important to determine the minimum ratio of 
polymer to genetic element in which the nucleic acid becomes completely complexed. 
Without complete complexation, genetic elements are exposed and quickly degraded by 
endogenous enzymes, rendering a loss of therapeutic potential. 43 The ability to bind and 
shelter genetic components is directly measured through a variety of gel-based assays. 
Gel retardation assays measure basic charge neutralization and help corroborate zeta 
potential studies. Polyplex formation does not necessarily indicate adequate protection of 
genetic cargo from degradation or protein replacement. DNase was utilized order to more 
directly measure the protective effects against endogenous enzymes. Endogenous 
nucleases are present in the body to rapidly deteriorate free DNA in the body to avoid 
unintended protein production and to mitigate risk of infectious genetic activity. 101 In 
order to determine the stability of the DDV complex in preventing competitive binding 
with large polyanions and to assess the ability of the complex to dissociate in order to 
free the nucleic acid cargo, a heparin competition assay was performed. Such an assay 
utilizes a strong anionic complex, heparin (pI=1), in a weight-to-weight manner relative 
to polymer, to determine at which charge ratio the genetic cargo is stripped from DDV.102 
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These investigations into the physicochemical properties of any potential polymeric 
system will provide metrics that help to determine likelihood of DDV delivery while also 
providing insight into the differences in performance in cell based testing.  
 
After identification of suitable candidates through physicochemical analysis, DDV drug 
and gene delivery performance are often assessed in relevant tissue lines for their 
potential induced cytotoxicity and therapeutic effect. High levels of unintended uptake 
and toxicity, poor drug delivery, low levels of transfection, or poor transgene expression 
in monoculture settings can suggest a poor candidate for a multifunctional DDV.  
 
The efficiency as a gene delivery carrier was assessed by transfection with complexes of 
pGFP (2µg/well) and PgP-(12k, 25k, 50k) in various N/P ratios using branched-25kD 
PEI (Sigma Aldrich, cat no: 408727) at N/P of 5/1 as a positive control, a commonly used 
standard notably used by Dr. Bae’s Group from University of Utah and Dr. Godbey’s 
group at Tulane University.  82,107  
 
Cells were transfected with media in a physiologically relevant 10% FBS serum 
condition, ~3% higher than blood serum concentration and allowed to incubate at 37 °C 
for 24 hours; at which time media was replaced to full media containing 10% FBS and 
1% Penicillin/Streptomycin. 31  
 
Drug delivery is a complex problem with an unknown number of total effectors. Any 
manipulation of an independent variable can result in the possibility of erroneous 
conflation. For example, positive alteration of the N/P ratio, a common form of 
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investigation in polymeric gene delivery, is usually undertaken with the notion that ratio 
of charge is the predominate factor is delivery regardless of the fact that such 
manipulation also changes concentration of the delivery vector and the charge 
distribution for each individual particle. It is known that even subtle changes in surface 
charge distribution can have profound effects in transfection outcomes and fails to 
capture the basic differences contributed by vector dose. This makes it easy to 
inappropriately conflate correlation down to a single factor of causation. One could easily 
mistake the change in charge ratio as the predominate factor driving in difference of 
outcome, while dose could be the sole driver. End point assays of metrics that are the 
result of multiple, potentially linked, factors can also result in similar outcomes despite 
varying mechanisms of actions. Generically, increasing one factor may diminish another 
factor in a way that results in the same outcome for the given timeframe. In the example 
of polymeric DDVs, increasing N/P ratio could increase particle surface charge in a way 
that decreases cell uptake rate, but since the number of complexed particles increased 
with the increase in dose, the resulting outcome could theoretically be the same, as each 
cell could end up with the same number of polyplexes. In a similar fashion, each cell type 
has variable response concerning charge distribution and its effect on uptake rate and the 
downstream endosome escape and subtle differences that drive performance go often 
overlooked. It is necessary to verify all permutations along a list of parameters to isolate 
each factors contribution in a particular model. With this in mind, transfections 
investigating the efficacy in delivering pDNA will be fixed to an equal dose of plasmid. 
Since an increase in number of micelles would also decrease average plasmid content per 
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polyplex and toxicity and gene delivery performance is driven by free amine content, two 
additional forms of DDV toxicity will be investigated: 1) All PgP polyplexes were 
formed at 25/1 N/P ratio and diluted 2) uncomplexed PgP; each regime was tested at 
equivalent concentrations of PgP as N/P 5/1, 15/1, 25/1 transfections. These 
investigations will help elucidate the primary driver of DDV cytotoxicity. Understanding 
the primary driver in DDV toxicity will help refine insights in later studies involving 
Doxorubicin loaded PgP and help inform the selection of the best PgP format in which to 
conjugate folate to as a targeting moiety for additional investigation as a multifunctional 
drug delivery vehicle.  
 
Before further investigation into drug loading or targeting, a pilot study was performed to 
determine the efficacy of PgP in vivo.  Immunodeficient mice were injected with MDA-
MB-435 ADR breast cancer cells in the mammary fat pad and were injected with 
PgP/pDNA polyplexes to determine the degree to which polyplex induced unwanted 
transfection in organs via migration in the bloodstream and the efficacy of nucleic acid 
delivery. 
    
Materials and Methods 
Three different molecular weights of poly(lactide-co-glycolide) (PLGA) were purchased 
from Durect Corporation (Pelham, AL), including PLGA 4 kDa, (50% lactide: 50% 
glycolide), 25kDa (75:25), and 50kDa (50:50), each with a carboxylic end group. 
Branched poly(ethylenimine) (PEI) (Mw 25 kDa), dicyclohexylcarbodiimide (DCC),  N-
hydroxysuccinimide (NHS), Thiazolyl Blue Tetrazolium Bromide, and RPMI 1640 were 
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purchased from Sigma (Milwaukee, WI). HPLC grade DMSO was purchased from Fisher 
Scientific (Pittsburg, Pennsylvania). Dialysis tubing (MWCO=50,000) was purchased 
from Spectrum (Houston, TX). QIAgen maxi plasmid purification kit was purchased 
from QIAgen (Valencia, CA). Plasmid DNA encoding the Monster Green Fluorescent 
Protein (phMGFP Vector: pGFP) and marker dye for gel electrophoresis (Blue/Orange 
6X Loading Dye) were purchased from Promega (Madison, WI). A molecular weight 
ladder (1kb DNA Ladder) and human recombinant insulin were purchased from Gibco 
BRL (Grand Island, NY). 100X stock solution of penicillin/streptomycin, and 0.05% 
trypsin/0.53 mM EDTA in Hank’s Balanced Salt Solution were purchased from 
Mediatech Inc. (Manassas, VA). EMEM, MCF-7 and MDA-MB-468 human breast 
cancer cells were purchased from ATCC (Manassas, VA). FBS was acquired from 
Atlanta Biologicals (Norcross, GA). Confocal	microscope	utilized	was	Olympus	IX81	(Center	Valley,	PA)	with	Hamamatsu	DCAM	(Middlesex,	NJ)	Camera	using	Metamorph	image	processing	software	(Center	Valley,	PA). Fluorodishes were 
purchased from World Precision Instruments, Inc. (Sarasota, Florida). MDA-MB-435 
(WT and ADR) human breast cancer cells were provided by Dr. Hassan Uludag’s group 
at the University of Alberta (Alberta, Canada).  
 
Synthesis and characterization of poly(lactide-co-glycolide)-g-poly(ethylenimine):  
PLGA was conjugated to the primary amine group of bPEI via ester bonding. PLGA (800 
mg, 200 µmole) was dissolved in 20 ml dried anhydrous DMF. N-hydroxysuccinimide 
(NHS, 27.6 mg, 240 µmole) and N,N’-Dicyclohexylcarbodiimide (DCC, 49.6 mg, 
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240µmole) were added to the reaction solution, and this mixture was stirred for 2 hours to 
activate the carboxylic end group of PLGA. The resulting precipitate, dicyclohexyl urea 
(DCU), was removed by filtration. bPEI (1.25 g, 50 µmole) was dissolved in 20 ml dried 
DMF. The activated PLGA solution was added dropwise to the bPEI solution over 30 
min, and then the mixture was allowed to react for 24 hours at room temperature while 
stirring. Poly(lactide-co-glycolide)-g-poly(ethylenimine) (PgP) was purified by dialysis 
against deionized water using a membrane filter (MWCO=50,000), centrifuged at 5,000 
rpm for 10 minutes to remove unreacted PLGA precipitate, solution was then lyophilized.  
 
Following synthesis and purification, the structure of PgP was determined by 1H-NMR 
on a Bruker 300 MHz using D2O as solvent. The structure and grafting ratio of PLGA to 
bPEI was confirmed by observing peaks (δ=2.4~3.5 (m, bPEI backbone -CH2), δ=1.4~1.6 
(d, 3H, PLGA -CH3), δ=4.3 (q, 1H, PLGA-CH), δ=3.9 (s, 2H, PLGA –CH2)).  
 
The molecular weight of PgP was determined by gel permeation chromatography. GPC 
was performed on an Ultrahydrogel 250 column (7.8x300 mm) and guard column (6x40 
mm) with water as the mobile phase. A 20-µl sample of PgP solution was utilized, with 
the flow rate set to 0.7 ml/minute. A Waters 1525 HPLC pump and Waters 2414 
refractive index detector were used. Dextrans at molecular weights of 5, 12, 25, 50 and 
80kDa were used as standards. 
 
Critical Micelle Concentration 
The critical micelle concentration (CMC) was determined using a dye solubilization 
method. Each weight of PgP was dissolved into a 1 mL aqueous solution at a variety of 
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concentrations, to which 10 uL of 0.4 mM DPH (1,6-diphenyl-1,3,5-hexatriene) solution 
was added and shaken for six hours in darkness. The absorbance at 356 nm was measured 
and plotted against the PGP concentration, and the CMC was determined as the point of 
intersection between linear extrapolations of the absorbance in low- and high-
concentration regions illustrating the concentration micelle complexes form. 
 
Particle size and surface charge of PgP/pDNA complex 
PgP/pGFP complexes were prepared using three different PgPs at various N/P (nitrogen 
atoms of polymer/phosphorus atoms of pDNA) ratios ranging from 5 to 30 (PgP-12k) and 
from 20 to 70 (PgP-25k and PgP-50k). Varying amounts of PgP solution were mixed 
with DNA (20 µg pGFP) solution and incubated for 30 min at room temperature. Particle 
size was determined by dynamic laser light scattering using Zeta PALS and reported as 
effective mean diameter. ζ-potential was measured electrophoretically using the same 
apparatus. 
 
Hemolytic activity 
The extent of hemolysis was determined by adapting a protocol used by Aravindan et al. 
103 Blood collected from Sprague-Dawley rats was combined with heparin (v/v ratio 1:10) 
was and then centrifuged at 700 x g for 20 minutes at 4ºC to separate buffy coat. The 
plasma was removed and the red blood cell pellets were washed three times using 150 
mM PBS (7.4 pH) with ten times the original volume of pellet, followed by aspiration of 
the supernatant post-centrifugation at 1000 x g for 10 minutes at 4ºC. Red blood cells 
were resuspended in 3% (w/v) solution in PBS for combination with polymers dissolved 
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in the same solution. Equal volumes (80 µL each) of cell solution and polymer were 
mixed and incubated for one hour at 37ºC. Following incubation, suspensions were 
centrifuged at 1000 x g for 10 minutes and 100 µL of supernatant was transferred to a 96 
well plate and absorbance was assessed at 540 nm using Synergy HT plate reader. 
Hemolysis was quantified using the following formula: (ASample-APBS)/(ATriton-X-
APBS)*100%, where ASample, APBS, ATriton are the absorbance of the sample, PBS, and 
Triton-X, respectively.  Triton-X and PBS treatments were utilized as positive and 
negative control, respectively.    
 
Hemoaggregation was analyzed using the procedure described by Delgado et. al. utilizing 
the previously described red blood cell isolation procedure. 104 Equal volumes (80 µL 
each) of cell solution and various polymer solutions were mixed and incubated for fifteen 
minutes at room temperature and then imaged. 
 
Plasmid amplification and purification 
Escherichia coli DH5α was transformed with plasmids encoding the Monster Green 
Fluorescent Protein (phMGFP Vector, pGFP) or beta-galactosidase (pSV40-pβGal, 
pβGal) and amplified in Lysogeny broth at 37°C overnight with shaking at 250 rpm. 
Plasmids were harvested using the Endofree Maxi Plasmid Purification Kit following the 
manufacturer’s protocol. Plasmid concentration and purity were assessed using a Biotek 
Synergy HT plate reader in conjunction with a Biotek Take3 microvolume plate system. 
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Gel retardation assays 
To evaluate pDNA binding, heparin competition, or DNase stability, PgP/pGFP or 
PEI/pGFP complexes were formed at various N/P ratios in RNase/DNase-free water and 
incubated for 30 minutes at 37°C to allow complex formation. To evaluate complex 
stability in the presence of DNase, PgP/pGFP polyplexes or pGFP alone was incubated in 
the absence or presence of DNase (2U) for one hour at 37°C. For the heparin competition 
assay, PgP/pGFP polyplexes or pGFP alone were incubated in the presence of increasing 
concentrations of heparin for one hour at 37°C. To complete each assay, the polyplexes 
were electrophoresed on a 1% (w/v) agarose gel for 25 minutes at 100 V, stained with 
ethidium bromide (0.5 µg / mL) and imaged on a UV illuminator (Alpha Innotech 
FluorChem SP imager). The 1kb DNA molecular weight ladder was purchased from 
Gibco. 
 
Cell Culture 
MCF-7, MDA-MB-468, MDA-MB-435 WT, and MDA-MB-435 ADR breast cancer 
cells  were all grown in media supplemented with 10% Fetal Bovine Serum (FBS) and 
1% penicillin-streptomycin at 37 °C with 5 % CO2. MCF-7 cells were grown using 
Eagle's Minimum Essential Medium supplemented with 10 µg/mL insulin  while MDA-
MB-468, MDA-MB-435 wild type, and MDA-MB-435 ADR) were grown using RPMI 
1640 media supplemented with 1% L-glutamine. Drug resistance was maintained in 
MDA-MB-435 ADR cells by treating them with 0.2 µg/mL of Doxorubicin-HCl once a 
week. 
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Transfection efficiency and cytotoxicity of PgP/pDNA complexes in breast cancer cells in 
vitro 
The transfection efficiency of 3 different formulations of PgP (PgP-12k, PgP-25k, and 
PgP-50k) was assessed by transfecting various breast cancer cell types with plasmid 
green fluorescent protein (pGFP) in media containing 10% serum. PEI/pDNA complexes 
at an N/P of 5/1 were also transfected as a positive control. Untreated cells were used as a 
negative control. Polyplexes were prepared by mixing PgP and pGFP, (2 µg/mL) at 
various N/P ratios and then incubating them for 30 minutes at 37°C. Cells (9x 105 
cells/well) were seeded in 12-well plates and allowed to attach overnight. The cells were 
then incubated with PgP/pGFP complexes in media containing 10% serum for 24 hours. 
Afterward, the media was removed and replaced with fresh media containing 10 % FBS 
and cells were incubated an additional 24 hours. The GFP-expressing cells were imaged 
using an inverted fluorescence microscope. Following imaging, cells were trypsinized 
and GFP-expressing cells were counted using a flow cytometer. The results were 
expressed as a percentage of transfected cells.  
 
Cytotoxicity was also analyzed by MTT assays in parallel experiments following the 
same transfection protocol. 48 hours post-transfection, cells were washed with PBS and 
incubated with 1 mL of serum-free media containing 240 µL of Thiazolyl Blue 
Tetrazolium Bromide in PBS (2 mg/mL) for 4 hours at 37 °C. After incubation, MTT-
containing medium was removed, and 1 mL of DMSO was added to dissolve the 
formazan crystals formed by live cells. Absorbance was measured at 570 nm using a 
Biotek Synergy HT plate reader. Cell viability was assessed according to the following 
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formula: Cell viability (%) = (OD 570 (sample)/ OD 570 (control)) X 100%. Statistical analysis 
was performed using ANOVA for multiple comparisons using Tukey’s Post Hoc analysis 
using Dunnet’s correction.  
 
MCF-7 cells were transfected with PgP-12k/pGFP at N/P ratio of 30/1 while the pGFP 
expression was evaluated by epifluorescent microscopy over 20 days to investigate the 
transfection duration. 
 
Determination of the driver of PgP toxicity 
Transfections investigating the efficacy in delivering pDNA were fixed to an equal dose 
of plasmid; an increase in number of micelles would also decrease average plasmid 
content per polyplex. PEI toxicity and performance is driven by free amine content. With 
this in mind two additional forms of DDV toxicity were investigated: 1) All PgP 
polyplexes were formed at 25/1 N/P ratio and diluted 2) uncomplexed PgP; each regime 
was tested at equivalent N/P 5/1, 15/1, 25/1 PgP transfection doses. 
 
Intracellular trafficking and nuclear localization study 
PgP-12k was conjugated with Rhodamine-123 in a manner similar to Yang et al. 11  
Rhodamine-labeled PgP-12k was mixed with PgP-12k (1:5 w/w ratio) for visualization. 
MDA-MB-435 WT and ADR cells (9x 105 cells/dish) were plated in Fluorodishes. 
Polyplexes were formed by mixing pGFP, and Rhodamine-labeled PgP-12k at N/P ratio 
of 25/1 and transfected as described above. Cells were fixed using 4% paraformaldehyde 
solution at 36 hours post-transfection, and nuclei were counterstained with 4',6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI). 
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Uptake poly (lactide-co-glycolide) -graft-polyethylenimine/siGLO nanoparticles (FA-
PgP) in MDA-MB-435 ADR breast cancer cells 
The siGLO Red transfection indicator, consisting of a fluorescently labeled siRNA 
duplex with a chemical modification for nuclear localization, was used to evaluate siRNA 
transfection efficiency. PgP/siGLO complexes (1 µg siGLO Red) at various N/P ratio 
were transfected in cells in 10% serum condition. bPEI/siGLO at N/P 5/1 was used as 
positive controls. The cells were incubated at 37 °C for 24 hours and then the media were 
replaced with fresh media containing 10 % FBS. At 4 and 24 hours post-transfection, 
siGLO Red-transfected cells were collected and assessed by flow cytometry and the 
results expressed as % uptake positive and mean fluorescence.  
 
Transfection efficiency of PgP/pDNA polyplexes in an athymic nude mouse breast cancer 
model in vivo 
Athymic nude mice (female, 25 grams) were anesthetized using isoflurane gas. MDA-MB-
435 ADR cell solution (1 x 106cells/50 µl PBS) was injected into four mammary fat pads 
per mouse. After four weeks, PgP/pGFP or PgP/pβgal polyplexes (10 µg, 20 µL) were 
intratumorally injected at an N/P ratio of 30/1. Naked pGFP or pβgal were used as negative 
controls. Seven days post-injection of polyplexes, animals were anesthetized using 
isoflurane gas and euthanized by CO2 asphyxiation. To evaluate GFP expression ex vivo, 
tumors and organs from mice treated with pGFP were excised and imaged using a Vevo 
IVIS Lumina XRMS In Vivo Imaging System. To evaluate β-galactosidase expression; 
tumors treated with pβgal were excised, frozen in OCT, sectioned, and stained using a β-
Gal staining kit to detect β-Gal+ transfected cells and imaged using an inverted 
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microscope. All surgical procedures and postoperative care were conducted according to 
NIH guidelines for the care and use of laboratory animals (NIH publication No. 86-23, 
revised 1996) and under the supervision of the Clemson University Animal Research 
Committee (Approved animal protocol no. AUP2015-025). 
Statistical analysis 
Statistical analysis was performed using ANOVA for multiple comparisons using 
Tukey’s Post Hoc analysis unless otherwise noted. A p-value of less than 0.05 was 
considered statistically significant. The data were represented as mean + SEM. 
 
Results and Discussion 
Three different PgPs were synthesized using procedure described in a previous work 
done by our group.  84 Briefly, the carboxylic acid group of PLGA was activated using N-
hydroxysuccinimide (NHS) and N,N’-Dicyclohexylcarbodiimide (DCC) and then reacted 
to the amine group of PEI. The resulting Poly (lactide-co-glycolide)–g-
poly(ethylenimine) (PgP) was purified by dialysis The structure of PgP was determined 
by 1H- NMR (300 MHz, Bruker) using D2O as a solvent (Fig 3.1).  
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Figure 3.1: 1H-NMR spectra of PgP-[12k, 25k, 50k] (A) PgP-12k (B) PgP-25k (C). PgP-
50k 
 
In our characterization of PgP-12k, we found that approximately three 4 kDa blocks of 
PLGA are grafted to one PEI and the molecular weight of PgP-12k was approximately 
38,681 Da measured by 1H-NMR and 38,168 Da measured by GPC. The analysis of PgP-
25k revealed that approximately one block of 25kDa PLGA was grafted to one PEI and 
the molecular weight of PgP-25k was approximately 49,275 Da measured by 1H-NMR 
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and 48,791 Da measured by GPC. Lastly, one block of 50kDa PLGA was grafted to one 
PEI and the molecular weight of PgP-50k was approximately 73,000 Da measured by 1H-
NMR. The nomenclature for each PgP was ascribed by the weight of PLGA per one PEI 
molecule. PgP-12k, PgP-25k, and PgP-50k, have the following PLGA compositions: 
three blocks of 4 kDa PLGA, one block of 25 kDa PLGA, and one block of 50 kDa 
PLGA, respectively (Table 3.1).  
 
Table 3.1: Table summarizing composition of PgP-(12k, 25k, 50k) 
 
PgP-12k PgP-25k  PgP-50k 
PLGA Weight (kDa) 4 25 50 
PLGA Repeats 3.6 0.96 0.96 
PLGA Weight (kDa) 14.4 24 48 
Total Weight (kDa) 39.4 49 73 
HLB 12.7 10 6.84 
 
These permutations provide an investigation across block length as well as block number. 
Both parameters have implications on the kinetics of the polymer in reference to micelle 
structure.  
 
Essentially, we have three similar compositions of a singular drug delivery vector. These 
vectors are self-assembled amphiphilic unimers; these unimers are comprised of an 
average number of hydrophobic blocks (PLGA) covalently bound to a hydrophilic block 
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(PEI). These PgP unimers form aggregates called micelles; of which the composition 
number and stereo-arrangement, is unique to each composite, and is ultimately resultant 
of thermodynamic and electrostatic equilibrium between the polymer and its 
environment.  
 
Micelle formation is a dynamic process that is in in continual flux, like any physical 
interaction between molecules and solvent. Unimers have distinct hydrophobic and 
hydrophilic domains that are in constant interaction with the solvent molecules. Below 
CMC, it is more energetically favorable for hydrophobic moieties interact with air than to 
sequester hydrophobic tails in a micellar solution. Once CMC/CMT conditions are met 
micellization occurs with colloidal suspensions providing hydrophobic space in solution. 
DPH exhibits differential ultraviolet absorbance depending upon its surrounding 
environment; an increase in absorbance associated with hydrophobic sequestration or 
incorporation into the hydrophobic space within micelles.  105   CMC was determined as 
the point of intersection between incorporated DPH associated with singularly dissolved 
unimer and the much brighter incorporated DPH localized in micelles. 
 
The CMCs of PgP were calculated to be 0.69 mg/ml (1.86 X 10 -5 M), 0.45 mg/mL 
(9.39x 10-6 M), and 0.16 mg/mL (2.07x 10-6 M) for PgP-12k, PgP-25k, and PgP-50k, 
respectively). HLB correlated negatively with an increase in hydrophobic block length 
and exceeded the stability range (~10-3-10-4M) of small molecular weight surfactants, 
such as sodium dodecyl sulfate (8.2 mM). The low CMC indicates a high degree of 
thermodynamic stability, a measure that describes tendency for unimers to undergo 
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micellization. The same forces that dictate thermodynamic stability are related to kinetic 
stability, the rate at which micelles disband into unimers once diluted below CMC. 
Polymeric micelles illustrate increased kinetic stability with increasing size of 
hydrophobic block. 25 Other factors such as core plasticity or incorporation of 
hydrophobic drugs may also slow destabilization, which is advantageous for increasing 
circulation times of a delivery vector for drugs and nucleic acids. 106    
 
 
Figure 3.2: Particle size and zeta potential of PgP-(12k, 25k, 50k) and PEI polyplexes 
 
The size and surface charge of PgP/pDNA polyplexes at various N/P ratios are shown in 
Figure 3.2. PgP/pGFP complexes were prepared at various N/P (nitrogen atoms of 
polymer/ phosphorus atoms of pDNA) ratios ranging from 1 to 30. DNA (20 µg pGFP) 
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and varying amounts of PgP were each separately diluted in 500 µl of deionized water. 
After 10 min, solutions were mixed and incubated for 30 min at room temperature. 
Particle size was determined by dynamic laser light scattering using Zeta PALS 
(Brookhaven Instruments Corp, Holtsville, NY) and reported as effective mean diameter. 
ζ-potential was measured electrophoretically using the same apparatus.  
 
The mean particle size of PgP-12k/pDNA polyplexes decreased with an increase in N/P 
ratio and was about 150-200 nm at an N/P ratio of 7.5/1 and above (Fig 3.2). Zeta 
potentials of PgP/pDNA complexes were dependent on the N/P ratio and were positively 
charged at an N/P ratio of 5/1 or greater suggesting that negatively charged plasmid DNA 
is completely neutralized by positively charged PgP above an N/P ratio of 5/1 (Fig 3.2). 
Particle size and ζ-potential of PgP-25k and PgP-50k were found to neutralize DNA at an 
N/P of 12/1 with particle sizes ranging from 200nm to 150nm respectively. All of which 
are similar to the size of bPEI/pGFP complexes (Fig 3.2). It is of note that in some size 
and zeta potential experiments a bimodal distribution of neutrally charged and positively 
charged aggregates was exhibited (data not shown). This phenomenon has been observed 
in other polymeric micelle systems, as primary aggregates undergo secondary 
conformation changes into larger complexes.106 
 
Size and surface charge characteristics of polyionic complexes are important in 
determining the fate of the delivery system both in terms of extracellular delivery, 
cellular uptake, and intracellular fate. 44 In addition to providing insight to charge 
dynamics between gene element and polymer zeta potential assessment can provide 
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insight to the potential of aggregation via self-attraction. With the presence both negative 
and positive charge components complexes with low zeta potentials run the risk of 
surface electrostatic repulsion being insufficient in overcoming attractive forces of 
negative moiety on surface of complex (nucleic acid) of one complex to the positive 
corona of another complex. 78 Such a situation increases the likelihood of flocculation, 
reducing concentration of drug within system and reducing efficiency.  
 
 
Figure 3.3: A) Gel retardation assay using PgP-(12k, 25k, 50k) /pGFP complexes. Lane 
1: DNA ladder, Lane 2:naked pDNA, Lane 3 -9: PgP/pGFP (N/P: 2.5, 5, 10, 15, 20, 25, 
30 respectively) B) DNase protection assay with PgP-(12k, 25k, 50k)/pGFP complexed at 
N/P 25/1. Lane 1:pGFP, Lane 2:pGFP with 2 units DNase, Lane 3: PgP-12k/pGFP, Lane 
4: PgP-12k/pGFP with 2 units DNase, Lane 5: PgP-25k/pGFP, Lane 6: PgP-25k/pGFP 
with 2 units DNase, Lane 7: PgP-50k/pGFP, Lane 8: PgP-50k/pGFP with 2 units DNase 
C) Heparin competition assay using PgP-(12k, 25k, 50k) /pGFP complexes. Lane 1: 
DNA ladder, Lane 2:naked pDNA, Lane 3: PgP/pGFP (N/P:25/1), Lanes 4-10: PgP-
12k/pGFP (N/P: 25/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 respectively) 
 
 
Minimum N/P ratios required for complex formation between PgP and pDNA were 
investigated using a gel retardation assay. PgP/pDNA complexes were formed at a 
variety of N/P ratios and the minimum ratio for complex formation was determined by 
identifying the lowest N/P ratio at which no pDNA migration was observed, 
A) 
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demonstrating complete binding of free pDNA by PgP.  PgP-12k, 25k, and 50k 
completely bound free pDNA at N/P ratios of 10/1 (Fig 3.3A). Binding strengths were 
further assessed in a Heparin competition assay. 
 
In order to determine the stability of the PgP/pDNA complex in preventing competitive 
binding with large polyanions and the ability of the complex to dissociate in order to free 
the nucleic acid cargo, a heparin competition assay was performed. PgP-25k polyplexes 
began to dissociate at a Heparin/pGFP weight ratio of 2/1, while PgP-12k and PgP-50k 
both began to dissociate at a weight ratio of 5/1 (Fig 3.3B). The additional weight of 
heparin required to dissociate PgP-12k and PgP-50k relative to PgP-25k, reflects the 
increased stability of these complexes over PgP-25k. PgP micelles composed of any 
weight PLGA have exhibited the ability to dissociate from pDNA, demonstrating the 
potential utility of PgP for delivery and release of nucleic acid cargo.  
 
Both gel retardation and heparin are indirect measure of protective ability of DDV. PgP-
12k, 25k, and 50k all exhibited protective effects against DNase-mediated degradation of 
pDNA at an N/P ratio of 25/1, demonstrating the potential of PgP to protect genetic cargo 
for in vivo delivery (Fig 3.3C).   
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Figure 3.4: A) Hemolytic activity of PEI, PgP-[12k, 25k, 50k] at 0.025, 0.05, 0.1, 0.25, 
0.5, 0.75, 1 mg/mL in 7.4 pH 150 mM phosphate buffered saline (PBS). Red blood cells 
collected from Sprague-Dawley rats. * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 
B) Hemoaggregation of red blood cells in 7.4 pH 150 mM PBS incubated with 1 mg/mL 
of PEI, PgP-[12k, 25k, 50k] for fifteen minutes 
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Hemolysis is a direct measure of cytotoxicity on erythrocytes, while hemoaggregation 
provides insight into the physical interactions of the delivery vehicle with solid elements 
in the blood. Both are important factors necessary to assess the safety of the delivery 
vehicle prior to in vivo evaluation.   Interestingly, increasing the dose of PgP at any MW 
between the concentrations 0.025 mg/mL to 0.5 mg/mL did not result in increased 
hemolysis, as was demonstrated with PEI. PgP-12k induced little to no hemolytic activity 
while both PgP-25k and 50k induced 4-7% hemolysis. The hemolytic activity of PEI 
generally increased with polymer concentration and ranged from ~10% at 0.025 mg/mL 
to ~40% at 0.5 mg/mL (3.4A). At 1 mg/mL, PgP-12k, 25k, and 50k induce some 
erythrocyte aggregation relative to untreated cells; however, it is to a far lesser degree 
compared to PEI at the same concentration (Fig 3.4B).   
 
Together, these results demonstrate that PgP micelles have minimal hemolytic activity, 
especially when compared to equivalent concentrations of PEI. However, the linearized 
block conjugates (25k and 50k) exhibited more hemolytic activity despite relatively 
reduced charge. This may suggest nanotopology has an effect, likely on a steric level to 
reduce blood cell exposure to primary amines. 
 
The transfection efficiency of pGFP and cytotoxicity of PgP-12k, PgP-25k, and PgP-50k 
polyplexes in MCF-7, MDA-MB-468, MDA-MB-435 WT and MDA-MB-435 ADR cells 
was determined by flow cytometry and MTT assays, respectively. These results are 
shown in Figure 3.5. PEI polyplexes at an N/P ratio of 5/1 were evaluated as a positive 
control and untreated cell were used as a negative control. Generally, there was a positive 
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correlation between N/P ratio and transfection efficiency, and a negative correlation 
between N/P ratio and cell viability. PgP polyplexes also achieved much higher 
transfection efficiencies in comparison to PEI polyplexes, which achieved maximum 
transfection of less than 5% in all cell lines (Fig 3.5). 
 
Figure 3.5: Transfection efficiency (primary axis) and metabolic activity (secondary axis) 
of three PgP /pGFP complexes at varying N/P ratios in (A) MCF-7, (B) MDA-MB-468, 
(C) MDA-MB-435 Wild Type, and (D) MDA-MB-435 ADR cells. * or ## P≤ 0.05, ** or 
## P≤0.01, *** or ### P≤0.001, **** or #### P≤0.0001 
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PgP-12k polyplexes demonstrated the highest levels of pGFP transfection in MCF-7 and 
MDA-MB-435 WT cells, with 54% and 65% transfection efficiency, respectively, at an 
N/P ratio of 30/1 (Fig 3.5). Although to a lesser degree, PgP-12k polyplexes were also 
able to transfect MDA-MB-468 and MDA-MB-435 ADR cells with transfection 
efficiencies of 30% and 35% at an N/P ratio of 30/1. PgP-12k demonstrated minimal 
cytotoxicity in all cell lines tested. The highest toxicity was observed in MDA-MB-435 
WT cells, with 75% viability at an N/P ratio of 30/1. For all other breast cancer cell lines, 
the viability ranged between 80-120% for all N/P ratios evaluated. 
 
PgP-25k polyplexes required higher N/P ratios to achieve transfection efficiency similar 
to PgP-12k polyplexes. Transfection of PgP-25k polyplexes was greatest for MCF-7 
cells, with a transfection efficiency of 50% at an N/P ratio of 70/1 (Fig 3.5). However, 
PgP-25k was not very effective in transfecting all other cell types evaluated. Transfection 
efficiencies observed for MDA-MD-468, MDA-MB-435 WT, and MDA-MB-435 ADR 
cells were approximately 3%, 13%, and 4%, respectively. Cytotoxicity of PgP-25k 
polyplexes was similar to measured values for PgP-12k polyplexes, with viability ranging 
between 75-120%. 
 
PgP-50k was the least efficient in transfecting pGFP into breast cancer cells lines when 
compared to PgP-12k and PgP-25k. Like PgP-25k, the highest transfection efficiency was 
observed in MCF-7 cells, with 30% transfection at an N/P ratio of 50/1 (Fig 3.5). PgP-
50k polyplexes achieved transfection efficiencies of only 6%, 4%, and 2% at the 
maximum N/P ratio tested in MDA-MB-468, MDA-MB-435 WT, and MDA-MB-435 
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ADR cells, respectively. Treatment with PgP-50k polyplexes resulted in a wide range of 
measured cell viabilities from 75% in MCF-7 cells up to 120% in MDA-MB-435 WT 
cells at N/P ratios from 20/1 to 70/1. 
 
 
Figure 3.6: Time-course study of GFP expression in MCF-7 cells with PEI/pGFP and 
PgP-12k/pGFP in 10% serum condition at 4, 8, 14, 20 days. Top: PEI/pGFP N/P 5/1, 
Bottom: PgP/pGFP N/P 30/1 
 
Transgene GFP expression was found to last up to 20 days in MCF-7 breast cancer cells 
(Fig 3.6). 
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Figure 3.7: Confocal microscopy depicting intracellular trafficking of Rhodamine-
PgP/pGFP polyplexes in MDA-MB-435 WT and MDA-MB-435 ADR breast cancer cells 
 
Intracellular uptake, nuclear localization and subsequent transfection were observed in 
both MDA-MB-435 WT and MDA-MB-435 ADR breast cancers via confocal 
microscopy 48 hours post transfection (Fig 3.7). 
 
Overall, the results demonstrate that PgP-12k was the most efficient vector for 
transfecting breast cancer cell lines in comparison to PgP-25k and PgP-50k. PgP-12k 
mediated high levels of pGFP transfection in MCF-7 cells and MDA-MB-435 WT cells 
and mediated moderate transfection in MDA-MB-468 and MDA-MB-435 ADR cells. 
PgP-25k and PgP-50k were only able to mediate transfection into MCF-7 cells, with PgP-
50k demonstrating the lowest efficiency. PgP-12k and PgP-25k were approximately 1.7-
fold more efficient in transfecting MCF-7 cells compared to PgP-50k. Further, PgP-12k 
polyplexes were at least 5-fold more efficient in transfecting all other cell lines in 
comparison to both PgP-25k and PgP-50k. 
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Differences in cell lines are result of differences in uptake and subsequent intracellular 
trafficking. The size distribution of polyplexes is a dynamic entity related to synthetic 
composition, initial formation conditions, temperature, pH, protein and salt contents.9 
Serum content is high in albumin, whose presence has been shown to have a strong 
detrimental effect on the kinetic stability of polymeric delivery due to induced 
aggregation effects and formation of a ternary structure.102,108 Differences in media 
composition between cell lines may have some effect on the aggregation but stronger 
effects are likely due to serum content, which remains constant throughout 
experimentation. These minute differences in size and charge may have more profound 
effects depending on each cell’s optimal trafficking modality. Altering the relative 
proportion of polyplexes trafficked to each endocytic pathway will have obvious effects 
dependent on the efficacy of each route, with optimal pathway conditions likely varying 
between cell lines.36 
 
Furthermore, cells that divide more quickly have been associated with improved 
transfection outcomes. Nuclear import and subsequent transcription are two rate limiting 
steps to transfection. 77,109 Nuclear pores generally only allow free trafficking of 
molecules under 9 nm in diameter or 50kD in size, much smaller than the observed size 
of polyplexes. 83,101 Magnitudes higher transfections have been associated with S or G2/M 
phases compared to other cell cycles. 110 During these phases genetic material is no longer 
sequestered within the nuclear envelope, thus it is now widely accepted that increased 
cell division and growth have a positive correlation with transfection success. 36 
Generally, observed cell division rates increase across MDA-MB-435 ADR, MDA-MB-
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468, MCF-7, and MDA-MB-435 WT cells. This observation may serve to explain some 
of the resulting transfection differences between lines.  
 
Within each experimental set, plasmid concentration is fixed to 2ug/well and increasing 
the amounts of PgP used in higher N/P ratios. With each increase of PgP there is also a 
decrease of relative number of plasmid copies compared to unimer number. Despite this 
fact, with each increase in dose there is increase in the percentage of cells positive. This 
would suggest that despite there being few plasmid copies per micelle the added 
functionality of increasing the vector somehow yields greater protein production. It has 
been shown that uncomplexed PEI, even added a few hours after initial polyplex 
exposure can enhance transfection up to 500 times. It is still not clear why but proposed 
explanations involve enhanced uptake of complexed PEI, improved endosomal escape, or 
activation of trafficking pathways more conducive to transfection.  77 The cytotoxic 
mechanism of PEI is still in contention. It has been observed that membrane exposure to 
primary amines has a destabilizing effect, which results in a decrease of metabolic 
activity. 111 PEI is more toxic in its free form due to increased numbers of exposed 
primary amines compared to PgP. 112 It is these free amines that have also been correlated 
to increased endosomal escape and transfection rates, regardless of mechanism. 77  
 
Initial micellization is driven by the presence of hydrophobic blocks. This effect reduces 
primary amine exposure via steric limitations induced by hydrophobic effect. Such a 
reduction is reflected in the higher N/P ratios required for complete charge neutralization 
when utilizing PgP compared to PEI. Microcytic regularity is partially enforced by 
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preformation of micelles prior to complexation with DNA. These motifs enforce 
regularity in the chaotic and multilayered aggregation process associated with DNA. 
Decreasing HLB across increasing PgP size dictates the morphology of these 
microstructures with star-like micelles being more limited by hydrophilic block sterics 
transitioning into tighter-cored crew-cut micelles, limited by hydrophobic block sterics. 
Particle size measurements reflect a reduction in aggregate size from ~200nm for PgP-
12k and PgP-25k to ~150nm for PgP-50k, potentially as a result of tighter cores 
associated with crew-cut micelles relative to star-like micelles allowing better polyplex 
compaction. With an HLB of 10, PgP-25k may represent a transition from star-like to 
crew-cut micelles. An increase in hydrophobic block length in one-block systems with a 
consistent hydrophilic block has been shown to increase aggregation number as well as 
core size while decreasing CMC. This however, often comes with a negative effect on the 
total number of micelles. 106 This transition has an effect final aggregate structure and 
may help explain the easier dissociation of genetic material associated with PgP-25k 
relative to PgP-12k and PgP-50k in Heparin competition assay as aggregate behavior 
potentially trends from more, loosely-associated to fewer, more strongly associated 
micelles.  
 
Use of lipophilic moieties to reduce primary amine exposure and membrane 
compatibility has been extensively investigated to mitigate polyplex toxicity. 113 
Enhanced transfection with PgP relative to PEI is partially due to a hybridization of 
reduced primary amine exposure and enhanced membrane compatibility induced by 
hydrophobic moieties. 
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Figure 3.8: Metabolic activity of three PgP /pGFP complexes in (A) MCF-7, (B) MDA-
MB-468, (C) MDA-MB-435 Wild Type, and (D) MDA-MB-435 ADR cells. PgP/pGFP 
complexes were formed at N/P 25/1 and both PgP alone and PgP/pGFP complexes were 
diluted down to concentration of PgP found in designated N/P equivalent  * P≤ 0.05, ** 
P≤0.01, *** P≤0.001, **** P≤0.0001 
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In cytotoxicity experiments designed to decouple N/P ratios from dose of PgP, PgP-12k 
and PgP-12k/pGFP complexes were not significantly cytotoxic in any ratio in any cell 
line (Fig 3.8). There were no significant differences in cytotoxicity between PgP-12k 
alone and PgP-12k/pGFP in any ratio equivalent. Using PgP-25k, similar cytotoxicities 
were observed in all ratios tested with no significant differences found between any 
groups. PgP-50k alone and PgP-50k/pGFP were only found to be significantly toxic at 
PgP-50k at PgP dose equal to a N/P 25/1. In MDA-MB-468 cells, neither PgP-12k nor 
PgP-12k/pGFP were significantly cytotoxic at any dose. PgP-25k and PgP-25k/pGFP 
induced significant cytotoxicity at 25/1. Unlike MCF-7 cells, PgP-50k was found to be 
significantly cytotoxic at all ratios tested in both formats. In MDA-MB-435 WT cells, 
PgP-25k, PgP-50k, and PgP-50k/pGFP were found to be significantly cytotoxic at all 
doses tested (p	≤ 0.0001). In MDA-MB-435 ADR cells, only PgP-50k/pGFP at 
equivalent doses 15/1 and 25/1 were able to be found statistically different from control. 
This study supports the notion that larger PgPs are more toxic per mole, regardless of N/P 
relationship. 
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Figure 3.9: Cell uptake of siGLO/PgP complexes in MDA-MB-435 ADR cells (A)% 
uptake (B) mean fluorescence value (F). 
 
In a siGLO uptake study in MDA-MB-435 ADR cells, as N/P ratio increased within each 
PgP type or as weight of PgP used at each N/P increased there was an increase in percent 
of cells positive for siGLO as well as the mean brightness of cells (Fig 3.9). This suggests 
that given equitable levels of nucleic acid components for any increase in polymer 
concentration there will be an increase in both the population of cells that uptake DDV as 
well as a greater amount of nucleic acid per each cell, despite the nucleic acid reduction 
relative to polymer. This study, taken together with cytotoxicity data suggests that, 
despite greater amount of PgP uptake associated with increased PgP weight there is a 
reduction in transgene expression. Indicating that differences in PgP-12k transfection vs 
PgP-25k and PgP-50k are likely the result of reduced endosomal escape or poor nuclear 
localization of pGFP plasmid. 
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Figure 3.10: Transfection efficacy of PEI/pβGal and PgP-12k/pβGal in MDA-MB-435 
ADR cells 
 
 
Prior to injecting PgP-12k polyplexes in vivo, transfection with pβGal pDNA transfection 
was undertaken in vitro. Observed transfection rates were highest in PgP-12k/pβGal with 
reduced transfection in PEI/pβGal and pβGal alone (Fig 3.10). 
 
 
Figure 3.11: GFP expression after local injection of PgP12k/pGFP in mice, excised tumor 
and organs at 1week post-injection 
 
Immunodeficient mice were injected with MDA-MB-435 ADR breast cancer cells in the 
mammary fat pad. Tumors were injected with naked pGFP or PgP-12k/pGFP polyplexes. 
One week later tumors and organs were excised. GFP was found to be concentrated in 
pβGal		 PEI/pβGal		 PgP-12k/pβGal		
Naked pGFP PgP-12k/pGFP polyplex 
Liver Spleen Kidney Heart/ Lung Brain Tumor 
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tumors with increased visible GFP expression in tumors injected with PgP-12k/pGFP 
relative to tumors injected with pGFP alone. Little to no GFP was expressed on surfaces 
of organs, suggesting limited exposure of injected pDNA to rest of the body via the 
circulatory system (Fig 3.11).  
 
 
Figure 3.12: Transfection efficacy of pβGal and PgP-12k/pβGal in MDA-MB-435 ADR 
tumors 
 
 
A similar study was performed using pβGal in lieu of pGFP. Excised tumor sections 
illustrate increased transfection in tumors injected with PgP-12k/pβGal polyplexes 
compared to naked pβGal alone (Fig 3.12). Both of these in vivo studies indicate that 
PgP-12k is potentially and effective DDV for nucleic acid delivery. 
 
Conclusions 
PgP was successfully synthesized and characterized utilizing a variety of PLGA lengths. 
In all cell lines and PgP types, transfection efficiency ascends with a rise in N/P ratio 
(sans the top end of PgP-12k in MCF-7 [30/1] and PgP-50k in MDA-MB-468 at highest 
pβGal		 PgP-12k/pβGal		
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N/P ratios tested [70/1]). As weight of PLGA component increased there was a decrease 
in transfection efficiency compared to its associated cytotoxicity. PgP-12k has ten to one 
hundred fold higher transfection efficiency relative to cytotoxicity than that of branched 
PEI-25k, known as the best non-viral gene carrier, in all cell lines tested in 10% serum 
condition. 86,114 This represents marked improvement of Dr. Bae’s (PLGA)-b-PEI 
micelles which exhibited a reduction in concentration of GFP produced compared to PEI 
N/P 5:1 in non-serum conditions. 114   
 
PgP-12k illustrates itself to be a superior polymeric gene delivery vector than the current 
gold standard PEI in more physiologically relevant conditions (10% serum) across wide 
variety of breast cancer contexts. 76 Utilization of longer PLGA blocks may increase 
hydrophobic drug loading capability but at the detriment to its ability to effectively 
deliver pDNA. As incorporation of a hydrophobic drug within the polymeric core would 
increase functionality of DDV, future studies involve loading of Doxorubicin within 
complexes. Increasing PLGA block length is expected to enhance drug-loading capability 
per weight of polymer and may redeem functionality of lesser transfecting PgP-25k and 
PgP-50k. Additionally, PgP-12k will be conjugated to folate to illustrate the feasibility of 
incorporating a targeting moiety. 
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CHAPTER FOUR 
EVALUATE POLY(LACTIDE-CO-GLYCOLIDE)-GRAFT-
POLYETHYLENIMINE (PgP) AS A DRUG CARRIER 
 
Introduction 
The composition of poly (lactide-co-glycolide) -graft-polyethylenimine (PgP) is 
described by increasing poly  (lactic-co-glycolic) acid (PLGA) ratios. PLGA exists as 
different blends of block copolymers from lactide (L) and glycolide (G) monomers. 
These blends are described by the relative number of blocks of each type whose 
nomenclature is derived from this proportion. PgP-12k and PgP-50k are comprised of 
50%:50% L to G while PgP-25k is comprised of 75:25 L to G. Lactide groups weigh per 
unit more because of additional methyl group within the structure. This additional 
hydrophobic branching results in greater hydrophobicity to some extent and may 
increased steric hindrance due to a more branched structure. 115 The reason for variable 
block composition is due to materials available. 
 
Beyond PLGA composition differences there also exist some synthetic differences 
between each type. PgP-12k is comprised of  ~3[.6] (4 kDa) blocks per 1 PEI. PgP-25k 
~1 (25 kDa) to 1 PEI and PgP-50 ~1 (50 kDa) to 1 PEI; yielding total weights of 38.6 
kDa, 49.2 kDa and 73 kDa for PgP-12k, PgP-25k, PgP-50k respectively (Table 3.1). 
Many chemotherapeutic drugs are hydrophobic. 9 This results in a diminishment of 
medical utility due to solubility limits, which may be improved via encapsulation within 
DDV. In this study, increasing amounts of hydrophobic PLGA were used load more 
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Doxorubicin (DOX) per mg of polymer. A fixed mass (1 mg/mL) of each PgP type was 
dissolved to a fixed volume (1 mL) and subjected to variable hydrophobic Doxorubicin 
content in order to determine optimal DOX loading procedure. In chapter 3, all 
transfections were fixed to an equal dose of plasmid; an increase in number of micelles 
would also decrease average plasmid content per polyplex. PEI toxicity and performance 
is associated with free amine content, with N/P 5/1 being cited as the most efficacious 
format with increased ratios incurring unacceptable toxicity; indicating the importance of 
both dose and form in nanomedicine. It was found larger PgPs are more toxic per mole, 
regardless of N/P relationship. It was then important to determine if this concept carries 
forward to it DOX loaded counterparts and additionally determine if DOX loaded PgP 
(complexed or uncomplexed) induces an equivalent cytotoxic response to DOX 
Hydrochloride (DOX HCl), a more water-soluble version of DOX often used 
chemotherapeutic treatment. These comparisons 1) provide further evidence that even 
within a refined context of “breast cancer” that our delivery goals are different relative to 
each target population, 2) illustrate that introduction of a new compound may assist or 
hinder advancement on other goals, 3) determine if PgP delivers effective dose to a 
current at-market counterpart DOX HCl, and 4) determine if effective dosages optimized 
for gene delivery can deliver a dose of DOX in sufficient quantity to induce a significant 
cytotoxic response. 
 
Materials and Methods 
Three different molecular weights of poly(lactide-co-glycolide) (PLGA) were purchased 
from Durect Corporation (Pelham, AL), including PLGA 4 kDa, (50% lactide: 50% 
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glycolide), 25kDa (75:25), and 50kDa (50:50), each with a carboxylic end group. 
Branched poly(ethylenimine) (PEI) (Mw 25 kDa), Dicyclohexylcarbodiimide (DCC),  N-
hydroxysuccinimide (NHS), Thiazolyl Blue Tetrazolium Bromide, Doxorubicin HCl, and 
RPMI 1640 were purchased from Sigma (Milwaukee, WI). Doxorubicin free base was 
purchased from MedKoo Biosciences (Chapel Hill, North Carolina). HPLC grade DMSO 
was purchased from Fisher Scientific (Pittsburg, Pennsylvania). Dialysis tubing 
(MWCO=50,000) was purchased from Spectrum (Houston, TX). QIAgen maxi plasmid 
purification kit was purchased from QIAgen (Valencia, CA). Plasmid DNA encoding the 
Monster Green Fluorescent Protein (phMGFP Vector: pGFP) and marker dye for gel 
electrophoresis (Blue/Orange 6X Loading Dye) were purchased from Promega (Madison, 
WI). A molecular weight ladder (1kb DNA Ladder) and human recombinant insulin were 
purchased from Gibco BRL (Grand Island, NY). 100X stock solution of 
penicillin/streptomycin, and 0.05% trypsin/0.53 mM EDTA in Hank’s Balanced Salt 
Solution were purchased from Mediatech Inc. (Manassas, VA). EMEM, MCF-7 and 
MDA-MB-468 human breast cancer cells were purchased from ATCC (Manassas, VA). 
FBS was acquired from Atlanta Biologicals (Norcross, GA). Fluorodishes were 
purchased from World Precision Instruments, Inc. (Sarasota, Florida). MDA-MB-435 
(WT and ADR) human breast cancer cells were provided by Dr. Hassan Uludag’s group 
at the University of Alberta (Alberta, Canada).  
 
Doxorubicin loading in Poly (lactide-co-glycolide)-g-poly(ethylenimine) 
Hydrophobic Doxorubicin freebase was dissolved into methanol to form a 10 mg/mL 
solution and then serially diluted. One hundred µl of various concentrations of DOX 
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solution was added to 1 mg/mL PgP-(12k, 25k, and 50k) solutions and shaken for 4 hours 
at 37 degrees Celsius. Samples stood at 37 degrees Celsius overnight to allow methanol 
to evaporate. The solution was filtered using a 0.2 µm filter to remove unloaded DOX. 
DOX loaded PgP (DOX/PgP) samples were then analyzed at 480nm absorbance and the 
amount of DOX loaded in PgP was calculated using a DOX standard curve. Samples 
were then frozen for further use. 
 
Cytotoxicity of Doxorubicin loaded PgP in various breast cancer cells 
Polyplexes were prepared by mixing various PgPs and pGFP (1 µg) at a N/P ratio of 25/1 
and then allowing them to incubate for 30 minutes at 37°C. Cells (2.25x 105 cells/well) 
were plated in 48-well plates and allowed to attach overnight. The cells were incubated 
with PgP, DOX/PgP, PgP/pDNA or DOX/PgP/pDNA in media containing 10% serum for 
48 hours; at which point media was replaced to 0.25 mL of serum-free media containing 
60 µL of MTT solution (2 mg/mL Thiazolyl Blue Tetrazolium Bromide in PBS) and 
incubated for 4 hours at 37 degrees. Doses apportioned via polymer concentrations at 
each N/P of PgP (5/1, 15/1, 25/1) using 0.5 µg pGFP/well; polyplexes formed at N/P ratio 
of 25/1 then subsequently diluted down to match PgP concentrations used in lower N/P 
ratio equivalent transfections. DOX HCl was used as control and the dose is equivalent to 
amount of DOX loaded by DOX/PgP at specified N/P ratio. 
 
Statistical analysis 
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Statistical analysis was performed using ANOVA for multiple comparisons using 
Tukey’s Post Hoc analysis unless otherwise noted. A p-value of less than 0.05 was 
considered statistically significant. The data were represented as mean + SEM. 
Results and Discussion 
Doxorubicin loaded in PgP-[12k, 25k, 50k] micelles correlated positively with an 
increase in amount available at the cost of efficiency (Fig 4.1A). Values shown in table 
4.1 exhibit maximum amount of DOX loaded relative to weight of PgP-12k, 25k, and 50k 
and associated efficiency, constrained by maximum solubility of DOX in methanol for 
chosen loading scheme (Fig  4.1B).  
 
 
Figure 4.1: (A) Doxorubicin loading in PgP-(12k,25k,50k) (B) Doxorubicin loading 
efficiency in PgP-(12k, 25k, 50k) 
 
Hydrophobic weight in each type of PgP is intrinsic to it composition i.e. as we ascend in 
PgP weight, there is greater proportion of molecular weight comprised of PLGA.   
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% Loaded by Weight % Efficiency 
PgP-12k 31.85 21.23 
PgP-25k 79.26 52.84 
PgP-50k 69.98 46.65 
Table 4.1: Table summarizing Doxorubicin loading in PgP-[12k, 25k, 50k] at 1 mg/mL 
with 1 mg/mL DOX 
 
 
As expected, with an increase in solute content (DOX), increasing amounts are loaded 
into PgP with decreasing efficiency (Table 4.1).  
 
 
PgP-12k PgP-25k PgP-50k 
Relative PLGA per N/P 1 1.24 1.85 
DOX Loading Ratio/PLGA 1 2.5 2.2 
Relative DOX dose per N/P 1 3.1 4.1 
Table 4.2: Table summarizing relative Doxorubicin loading amounts in PgP-[12k, 25k, 
50k] 
 
There is approximately 2.5 times DOX loading observed in PgP-25k and 2.2 times 
loading in PgP-50k relative to PgP-12k (Table 4.2). Unloaded DOX was removed via 0.2 
µm filtration. The ability to undergo 0.2 micron filtration is another desirable quality for a 
DDV, as it can significantly reduce manufacturing costs. 10   
 
Equal concentrations of polymer were dissolved above CMC (1 mg/mL). The 
composition of each different polymer yields increasing PLGA content positively 
correlated to hydrophobic block length. PLGA weight ratios between PgP-12k, PgP-25k 
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(1.47x PLGA/mol), and PgP-50k (2x PLGA/mol) samples begins to explain loading 
differences but this difference is insufficient to attribute all additional loading effects 
considering the relatively increased amount of DOX loading against additional PLGA 
content observed in PgP-25k (2.5x DOX loading/mol) vs PgP-50k (2.2x DOX 
loading/mol) (Table 4.2). PgP-25k has a higher percentage lactide composition in its 
PLGA, increasing hydrophobic character, potentially facilitating drug loading.  However, 
no additional imbued multiplicity of loading per lactide will ever explain the observed 
difference in loading. Therefore, there must be some additional factor at play.  
 
Particle size measurements at higher N/P ratios reflect a reduction in polyplex size from 
~200nm for PgP-12k and PgP-25k to ~150nm for PgP-50k, potentially as a result of 
tighter cores associated with crew-cut micelles relative to star-like micelles (Fig 3.2).  
 
This suggests that relative aggregate core volume differences can potentially be 
elucidated in a comparison of DOX loading relative to PLGA weight and molar PgP 
content. In loading conditions, the molar content of PgP-25k and PgP-50k relative to 
PgP-12k are 0.75 and 0.5 for PgP-25k and 50k respectively. Relative PLGA content in 
loading conditions are 1.47x and 2x for PgP-25k and PgP-50k. This suggests PgP-25k 
and PgP-50k hydrophobic space is 1.7x and 1.1x that of PgP-12k per PLGA molecule 
Decreasing HLB correlated with increasing PgP size enforces the morphology of these 
microstructures, star-like micelles being more limited by hydrophilic block sterics 
transitioning (~HLB=10) into tighter-cored crew-cut micelles, limited by hydrophobic 
block sterics. Below an HLB of 10, an increase in hydrophobic block length in one-block 
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systems with a consistent hydrophilic block has been shown to increase aggregation 
number as well as core size while decreasing CMC. This however, often comes with a 
negative effect on the total number of micelles. 106 Differences in loading could be the 
result from the effects of increasing PLGA block length: decreasing CMC, increasing 
unimer proportion in micelle form, decreasing number of total micelles as increased 
aggregation number results in more unimers per micelle. The apparent lesser loading in 
PgP-50k compared to PgP-25k may be the byproduct of less numerous but larger and 
more tightly cored micelle population, resulting in less overall hydrophobic space. 
Increased thermodynamic stability may be imbued with the addition of a hydrophobic 
drug such as DOX. 46    
 
DOX doses in free or complexed form were enough to induce significant cytotoxicity in 
all groups and doses except MDA-MB-435 ADR. In all groups, except in PgP-12k and 
PgP-25k transfections in MDA-MB-435 ADR cells, DOX loaded PgP groups of any 
weight were significantly more cytotoxic then the control and their PgP counterparts. No 
differences were found comparing free PgP versus complexed PgP in any group, dose, or 
cell line further supporting chapter 4 findings that dose has more bearing on cytotoxicity 
than N/P ratio.  
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Figure 4.2: Cytotoxicity of Doxorubicin HCl, PgP-(12k, 25k, 50k), PgP-(12k, 25k, 50k) 
/pGFP, Doxorubicin loaded PgP-[12k, 25k, 50k], Doxorubicin loaded PgP- 
(12k, 25k, 50k) /pGFP complexes in (A) MCF-7, (B) MDA-MB-468, (C) MDA-MB-435 
Wild Type, and (D) MDA-MB-435 ADR cells. Concentration of Doxorubicin HCl used 
was equivalent to amount of Doxorubicin used in DOX loaded PgP groups. PgP/pGFP 
complexes were formed at N/P 25/1 and both PgP alone and PgP/pGFP complexes were 
diluted down to concentration of PgP used in designated N/P equivalent. * P≤ 0.05, ** 
P≤0.01, *** P≤0.001, **** P≤0.0001 vs control, * P≤ 0.05, ** P≤0.01, *** P≤0.001, 
**** P≤0.0001 vs PgP or PgP/pGFP counterpart, é  P≤ 0.05, éé P≤0.01, ééé P≤0.001, 
éééé P≤0.0001 vs equivalent DOX HCl dose 
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In MCF-7 cells, there were no significant differences between toxicity of DOX/PgP-12k 
and DOX/PgP-12k/pGFP and the equivalent dose of DOX HCl. DOX/PgP and 
DOX/PgP/pGFP were significantly more cytotoxic than its PgP counterparts at all doses, 
which were only able to be found cytotoxic in PgP-50k 25/1 equivalent. This suggests 
vector toxicities are primarily due to the addition of DOX in MCF-7 cells (Fig 4.2A).  
 
In MDA-MB-468 cells, DOX-loaded PgP of any form was more cytotoxic than its PgP 
counterpart. DOX HCl was more toxic than DOX/PgP-12k/pGFP in 5/1 and 15/1 
equivalent dose ranges with comparable cytotoxicity noted in DOX/PgP-12k/pGFP at 
25/1 dose and all DOX/PgP-12k doses. The DOX/PgP-12k/pGFP group was found to be 
significantly less cytotoxic than DOX HCl at 5/1 and 15/1 but was equitably cytotoxic at 
25/1 dose. PgP toxicity versus control was only significant at PgP-25k and PgP-
25k/pGFP at 25/1 dose and PgP-50k and PgP-50k/pGFP at all doses with DOX loaded 
counterparts all inducing greater cytotoxicity, suggesting a large part of vector toxicity is 
due to loaded DOX (Fig 4.2B). 
 
MDA-MB-435 WT cells, all permutations were found to be significantly cytotoxic, 
however, DOX loaded counterparts all induced greater cytotoxicity, again suggesting a 
large part of vector toxicity is due to loaded DOX (Fig 4.2C). 
 
In MDA-MB-435 ADR cells, DOX/PgP-12k groups induce comparable cytotoxicities 
than their DOX HCl counterparts at all doses tested. DOX/PgP-25k are comparably 
cytotoxic at 5/1 and 15/1 and more cytotoxic at 25/1 than their DOX HCl counterpart (p	
≤0.0001 for DOX/PgP-25k and DOX/PgP-25k/pGFP respectively). Only DOX/PgP-25k 
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of either form or DOX/PgP-50k of either form were significantly cytotoxic over PgP 
counter parts. DOX/PgP-50k was less cytotoxic compared to DOX HCl at 5/1 dose while 
DOX/PgP-50k/pGFP at 25/1 dose was significantly more cytotoxic (Fig 4.2D).  
 
In the comparison of cytotoxicities, there were only divergences seen in MDA-MB-435 
wild type in PgP-12k dose equivalency of 25/1 and PgP-25k at N/P equivalence of 5/1 in 
PgP/pGFP and PgP alone groups. However, there were more profound differences in 
comparisons with DOX loaded groups. Interestingly, in MCF-7 and MDA-MB-435 lines, 
introduction of DOX into the system diminished GFP expression while the opposite 
effect occurred in MDA-MB-468 cells, where it was observed in greater quantities (data 
not shown). This may be the result of alternative endocytic dispersion profiles exposing 
more pDNA to nuclear machinery, or possibly an effect of DDV’s differed kinetic 
evolution with incorporation of DOX (Fig 4.2). 
 
The dosages applied at the 5/1 equivalent dosage for DOX-loaded groups in each regime 
were not enough to induce a LD50 response but in the case of MDA-MB-468’s and 
MDA-MB-435 WT cell lines was enough for all other applied doses. For MCF-7’s there 
seemed to be a thresholding of dose; while MDA-MB-435 ADR’s illustrated a 
proliferative response after some dose. Additionally, DOX loaded groups tended to 
follow toxicity curves more closely related to DOX HCl. While gene therapy seeks non-
toxic vectors, this is may not the goal in enhancing chemotherapeutic delivery. In this 
context, pDNA and DOX are co-administered and requires similar nuclear co-localization 
to be effective. In transfection studies, uptake profiles and toxicities of PgP micelles 
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appear to be most strongly correlated with DDV concentration. It is likely that the same 
groups that receive adequate polyplex to induce GFP transfection also will be the same 
populations that get increased DOX loaded PgP micelles, inducing greater cytotoxicity. 
Thus, polymer induced cytotoxicity via exposure to free primary amines may be less of a 
concern when incorporating a cytotoxic chemotherapeutic, assuming differential 
trafficking to target cancer populations. It is with this mind, PgP-12k will be conjugated 
to folate to illustrate the feasibility of incorporating a targeting moiety in an effort to 
selectively channel DDVs towards targeted cancerous populations. 
 
All things considered, this reinforces the concept the “magic bullet” is not a singular 
entity but rather a dynamic system and provides further evidence that the introduction of 
a new compound may assist or hinder advancement on other goals; even within a refined 
context of “breast cancer” we can clearly see delivery goals are specific to each target 
population. 
 
Conclusions 
Higher PLGA percentage was correlated with greater overall DOX loading per mg, 
potentially redeeming functionality of lesser transfecting PgP-25k and PgP-50k compared 
to PgP-12k. In doses optimized for transfection, Doxorubicin loaded PgPs were able to 
induce increased or similar cytotoxicity compared its free drug counterpart in MCF-7, 
MDA-MB-468, and MDA-MB-435 ADR lines and was able to induce over a LD50 
response in MDA-MB-468 and MDA-MB-435 WT cells. Comparable performance to 
free DOX suggests adequate incorporation of chemotherapeutic agents and with vastly 
 81 
improved transfection rates further supports PgP as a candidate for a multifunctional 
delivery system targeted towards breast cancer. 
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CHAPTER FIVE 
SYNTHESIZE AND CHARACTERIZE FOLATE FUNCTIONALIZED 
POLY(LACTIDE-CO-GLYCOLIDE)-GRAFT-POLYETHYLENIMINE 
NANOPARTICLES (FA-PgP) AS DRUG AND siRNA CARRIER FOR 
COMBINATORIAL THERAPY FOR THE EFFICIENT TREATMENT OF 
VARIOUS TYPES OF BREAST CANCER CELLS IN VITRO 
 
Introduction   
An increase in efficacy alone was insufficient in creating a delivery system that 
minimized therapeutic risk. Therefore, targeted therapies were set forth to further mediate 
specific delivery and promote cell internalization in a cell specific fashion. The addition 
of a targeting ligand has been long sought as an answer to specificity problems. However, 
because of the similar genetic profile cancer shares with its host, the existence of an 
exclusive moiety has yet to be discovered. Fortunately, there are a plethora of 
overexpressed moieties and transporters that are associated with common cancer types 
that can easily be conjugated to polymeric micelles. The ultimate goal of chemical based 
interventions is to accumulate enough of agent in target population to resolve existence 
with minimal damage to the host’s healthy populations. Because of their selective 
upregulation in some cancers and relative absence in normal tissue; surface proteins such 
as Human Epidermal Factor-2 (HER-2), prolactin, and folate receptors have been utilized 
as a means of actively transporting DDV’s into cells 47.   
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Some cancers possess unregulated extracellular receptors that are relatively absent in 
normal tissue; folate receptor alpha is an exemplar protein and has been frequently 
utilized as a means of selectively transporting DDV’s into cells. 47 Folate (FA) is an 
essential cofactor to DNA replication and is needed in large quantities by rapidly dividing 
cancer masses. Elevated levels of folate receptor (up to 100x expression) are correlated 
with aggressive cancers in the brain (75% of cases), ovaries (90%), lung (37%) and breast 
(32%).61,62 Breast cancers positive for folate receptor alpha overexpression (FA+) are 
associated with grim outcomes. 63 Furthermore, triple negative breast cancers represent a 
cohort of breast cancers that lack defined targeted therapeutic approach and have been 
also noted to have (FA+) in over 80% of cases. 64-66 Fortunately, both alpha and beta 
folate receptors (~38 kDa) exhibit limited distribution in normal tissues. 61 This level of 
upregulation and relative tissue specificity compounded with the great binding affinity of 
folate (Kd = 10-10 M), makes folate an attractive ligand to add targeting functionality to 
DDV’s. 67 There is little difference in the mechanism by which free folate and folate-
conjugated particles are trafficked. Free folate (and folate conjugated particles) initiates 
active transport into cell and is moved along the endosomal pathway; thus allowing 
conjugated DDV’s containing branched PEI to escape endosomal degradation. 47,67 
 
Over the pasts few decades three subsequent generations of non-viral delivery vectors 
have been engineered to address the shortcomings of previous technologies and 
incorporate lessons learned from a continuously evolving understanding of the delivery 
challenges associated with drug resistant breast cancer. 71 Initially relying solely on 
passive diffusion via the EPR effect, it became clear that further modification would be 
 84 
required to sufficiently increase intracellular accumulation. 72 This addition of active 
targeting via antibody or small molecule ligands improved the specificity of DDVs, but 
still left much to be desired in therapeutic efficacy. 73 It is currently recognized that a 
multifunctional drug delivery system that interacts with the target in a combinatorial way, 
i.e. co-delivery of a variety of genetic therapeutics and conventional pharmacological 
agents is necessary to address the complexities of breast cancer treatment in an effective 
manner. 1, 13  
 
Proposed is a unique combination of the amphiphilic copolymer, poly  (lactic-co-
glycolic) acid-g-polyethylenimine) (PgP) micelle delivery system as a flexible platform 
technology. PgP theoretically has potential advantages as a delivery system: 1) it should 
maintain some degree of morphological regularity as a result of associated 
thermodynamic forces, potentially limiting primary amine exposure via steric hindrance 
reducing DDV toxicity 2) its hydrophobic core can serve as a reservoir for hydrophobic 
anticancer drugs 3) its positively charged PEI hydrophilic shell could be used for 
complexation with negatively charged nucleic acids (therapeutic plasmid DNA or 
siRNA) which may further reduce primary amine exposure and DDV toxicity, and  4) 
targeting moieties can be easily conjugated on the surface of micelle. 84,85  
 
The addition of folate moiety (FA-PgP) will increase specificity of DDV, resulting in 
fewer systemic side effects and help establish a standardized protocol for the 
incorporation of therapeutically relevant targeting moieties to PgP’s structure.  
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In chapter 3, it was found that compared to the current gold standard of non-viral gene 
therapies, branched PEI25k, PgP-12k exhibits increased transfection and reduced 
cytotoxicity in tested breast cancer lines. 76. It was also found larger PgPs are more toxic 
per mole, regardless of N/P relationship. In chapter 4 it was then determined this concept 
carries forward to it DOX loaded counterparts. Confirmation that dose is more critical 
than form will again be sought in FA-conjugated PgP-12k and will be investigated in a 
similar manner before commencing siRNA studies. Delivering P-glycoprotein (ABCB1) 
targeted siRNA via complexation with PgP-12k should reduce efflux pump quantity and 
assist in the mitigation of drug resistance. Doxorubicin loaded FA-PgP-12k/ABCB1 
siRNA complexes will be a potential targeted therapeutic intervention developed from 
PgP designed to overcome drug resistant breast cancer more safely and substantially 
improve the length and quality of life of cancer victims. Success of this pilot study 
unveils the potential of PgP DDV constructs to deliver multidrug, multigene-targeted 
cocktails, improving upon the treatments of today and evolving with the personalized 
needs of the medicine of tomorrow.100 
 
Materials and Methods 
Three different molecular weights of poly(lactide-co-glycolide) (PLGA) were purchased 
from Durect Corporation (Pelham, AL), including PLGA 4 kDa, (50% lactide: 50% 
glycolide), 25kDa (75:25), and 50kDa (50:50), each with a carboxylic end group. 
Branched poly(ethylenimine) (PEI) (Mw 25 kDa), Dicyclohexylcarbodiimide (DCC),  N-
hydroxysuccinimide (NHS), Thiazolyl Blue Tetrazolium Bromide, Doxorubicin HCl, 
folate, cysteamine-HCL,	and RPMI 1640 were purchased from Sigma (Milwaukee, WI). 
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Doxorubicin free base was purchased from MedKoo Biosciences (Chapel Hill, North 
Carolina). Malmide-PEG-SVA	was	acquired	from	Laysan	Bio	Inc.	(Arab,	AL).	Rotovapor	RII	was	purchased	from	Bucci	(Switzerland).	Paraformaldehyde,	chloroform,	dimethyl	sulfoxide	and	ethyl	acetate	were	purchased	from	Acros	(Geel,	Belgium).	HPLC grade DMSO was purchased from Fisher Scientific (Pittsburg, 
Pennsylvania). Dialysis tubing (MWCO=50,000) was purchased from Spectrum 
(Houston, TX). QIAgen maxi plasmid purification kit was purchased from QIAgen 
(Valencia, CA). Plasmid DNA encoding the Monster Green Fluorescent Protein 
(phMGFP Vector: pGFP) and marker dye for gel electrophoresis (Blue/Orange 6X 
Loading Dye) were purchased from Promega (Madison, WI). A molecular weight ladder 
(1kb DNA Ladder) and human recombinant insulin were purchased from Gibco BRL 
(Grand Island, NY). 100X stock solution of penicillin/streptomycin, and 0.05% 
trypsin/0.53 mM EDTA in Hank’s Balanced Salt Solution were purchased from 
Mediatech Inc. (Manassas, VA). Confocal	microscope	utilized	was	Olympus	IX81	(Center	Valley,	PA)	with	Hamamatsu	DCAM	(Middlesex,	NJ)	Camera	using	Metamorph	image	processing	software	(Center	Valley,	PA).	EMEM, MCF-7 and 
MDA-MB-468 human breast cancer cells were purchased from ATCC (Manassas, VA). 
FBS was acquired from Atlanta Biologicals (Norcross, GA). Fluorodishes were 
purchased from World Precision Instruments, Inc. (Sarasota, Florida). MDA-MB-435 
(WT and ADR) human breast cancer cells were provided by Dr. Hassan Uludag’s group 
at the University of Alberta (Alberta, Canada).  
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Synthesis and Characterization of folate functionalized PgP 
Synthesis of FA-PEG-PgP-12k (FA-PgP-12k) was performed using a method similar to 
the synthesis of FA-PEG-PEI published by Zhang et al. in 2010, differing only in size of 
PEG based spacer and final conjugation to PgP-12k rather than PEI (Fig 5.1). 40 
 
  
Figure 5.1: Scheme of synthesis of generic FA-PgP 
  
FA-NHS:  Under darkness, 40 mL anhydrous DMSO was utilized as a solvent and stirred 
continuously to completely dissolve one gram of folate and 5 mL anhydrous 
triethylamine. Once homogeneous, 0.313g of NHS and .561g of DCC were introduced to 
the solution and allowed to mix for 48h. Product was collected via precipitation with 300 
mL of ethyl acetate following filtration with a fine pore filter. FA-NHS was then purified 
by two washes of ethanol and an additional precipitation in ether.  
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FA-SH:  Again using DMSO as a solvent (25mL), 450 mg of FA-NHS, 105 mg of 
cysteamine-HCL and 4.5 mL of anhydrous triethylamine were combined in darkness and 
stirred overnight. Product was further purified via two washes of ethanol and a 
subsequent precipitation in ether.  
FA-PEG-NHS:  200 mg of Mal-PEG-SVA and 56 mg of FA-SH were individually 
dissolved using 8 mL of phosphate buffered saline as a diluent. The reaction was allowed 
to proceed overnight at 35 degrees C after combining solutions with 100 µl of 
triethylamine. Precipitate was extracted with chloroform and excess solvent removed via 
vacuum evaporation. Final product was collected via ether precipitation.  
FA-PgP-12k: Stirring in darkness for 48 hours, 2.5mL anhydrous DMSO was utilized to 
dissolve 45 mg of FA-PEG-NHS and 517mg of PgP-12k or 346mg of bPEI to synthesize 
FA-PgP-12k or FA-PEI respectively. Products were then dialyzed against water 
(MWCO=50,000) and lyophilized before redissolved in chloroform and precipitated in 
ether twice.  
 
Gel retardation assays 
To evaluate pDNA binding, PgP-12k, FA-PgP-12k, one part FA-PgP-12k to two parts 
PgP-12k by weight (same format as FA-PgP-12k MIX used in transfection experiments 
discussed in the latter portion of this chapter), and one part FA-PgP-12k to four parts 
PgP-12k by weight/pGFP polyplexes were formed at various N/P ratios (N/P: 2.5, 5, 7.5, 
10, 12.5, 15, 17.5/1) in RNase/DNase-free water and incubated for 30 minutes at 37°C to 
allow polyplex formation. For the heparin competition assay, PgP-12k, FA-PgP-12k, one 
part FA-PgP-12k to two parts PgP-12k by weight, and one part FA-PgP-12k to four parts 
 89 
PgP-12k by weight/pGFP polyplexes or pGFP alone was incubated in the presence of 
increasing concentrations of heparin for one hour at 37°C at N/P ratio 15/1. Heparin 
competition assays were also performed using PgP-12k, FA-PgP-12k/pGFP polyplexes at 
N/P 30/1 and FA-PgP-12k and one part FA-PgP-12k to two parts PgP-12k by 
weight,/pGFP polyplexes at N/P 25/1. To complete each assay, the polyplexes were 
electrophoresed on a 1% (w/v) agarose gel for 25 minutes at 100 V, stained with ethidium 
bromide (0.5 µg / mL) and imaged on a UV illuminator. 
 
To evaluate siRNA binding, PgP-12k, FA-PgP-12k, one part FA-PgP-12k to two parts 
PgP-12k by weight, and one part FA-PgP-12k to four parts PgP-12k by weight/siABCB1 
polyplexes were formed at various N/P ratios (N/P: 2.5, 5, 7.5, 10, 12.5, 15, 17.5/1) in 
RNase/DNase-free water and incubated for 30 minutes at 37°C to allow complex 
formation. For the heparin competition assay, PgP-12k, FA-PgP-12k, one part FA-PgP-
12k to two parts PgP-12k by weight,, and one part FA-PgP-12k to four parts PgP-12k by 
weight/siABCB1 polyplexes or siABCB1 alone was incubated in the presence of 
increasing concentrations of heparin for one hour at 37°C at N/P ratio 15/1. Heparin 
competition assays were also performed using PgP-12k/pGFP polyplexes at N/P 30/1 and 
PgP-12k, FA-PgP-12k/pGFP polyplexes at N/P 60/1. To complete each assay, the 
polyplexes were electrophoresed on a 1% (w/v) agarose gel for 25 minutes at 100 V, 
stained with ethidium bromide (0.5 µg / mL) and imaged on a UV illuminator (Alpha 
Innotech FluorChem SP imager). The 1kb DNA molecular weight ladder was purchased 
from Gibco (Grand Island, NY). 
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Hemolytic activity 
The extent of hemolysis was determined by adapting a protocol used by Aravindan et al. 
103 Blood collected from Sprague-Dawley rats was combined with heparin (v/v ratio 1:10) 
was and then centrifuged at 700 x g for 20 minutes at 4ºC to separate buffy coat. The 
plasma was removed and the red blood cell pellets were washed three times using 150 
mM PBS (7.4 pH) with ten times the original volume of pellet, followed by aspiration of 
the supernatant post-centrifugation at 1000 x g for 10 minutes at 4ºC. Red blood cells 
were resuspended in 3% (w/v) solution in PBS for combination with polymers dissolved 
in the same solution. Equal volumes (80 µL each) of cell solution and polymer were 
mixed and incubated for one hour at 37ºC. Following incubation, suspensions were 
centrifuged at 1000 x g for 10 minutes and 100 µL of supernatant was transferred to a 96 
well plate and absorbance was assessed at 540 nm using Synergy HT plate reader. 
Hemolysis was quantified using the following formula: (ASample-APBS)/(ATriton-X-
APBS)*100%, where ASample, APBS, ATriton are the absorbance of the sample, PBS, and 
Triton-X, respectively.  Triton-X and PBS treatments were utilized as positive and 
negative control, respectively.    
 
Hemoaggregation was analyzed using the procedure described by Delgado et. al. utilizing 
the previously described red blood cell isolation procedure. 104 Equal volumes (80 µL 
each) of cell solution and various polymer solutions were mixed and incubated for fifteen 
minutes at room temperature and then imaged. 
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Plasmid amplification and purification 
Escherichia coli DH5α was transformed with plasmids encoding the Monster Green 
Fluorescent Protein (phMGFP Vector, pGFP) or beta-galactosidase (pSV40-pβGal, 
pβGal) and amplified in Lysogeny broth at 37°C overnight with shaking at 250 rpm. 
Plasmids were harvested using the Endofree Maxi Plasmid Purification Kit following the 
manufacturer’s protocol. Plasmid concentration and purity were assessed using a Biotek 
Synergy HT plate reader in conjunction with a Biotek Take3 microvolume plate system. 
 
In vitro transfection efficiency and cytotoxicity of folate-functionalized poly  (lactic-co-
glycolic) acid-g-polyethylenimine) complexes in various breast cancer cells 
Cell Culture: MCF-7, MDA-MB-468, MDA-MB-435 wild-type (WT), and MDA-MB-
435 Doxorubicin (ADR) resistant cells  were all grown in media supplemented with 10% 
Fetal Bovine Serum (FBS) and 1% penicillin-streptomycin at 37 °C with 5 % CO2. MCF-
7 cells were grown using Eagle's Minimum Essential Medium supplemented with 10 
µg/mL insulin  while MDA-MB-468, MDA-MB-435 wild type, and MDA-MB-435 
ADR) were grown using RPMI 1640 media supplemented with 1% L-glutamine. Drug 
resistance was maintained in MDA-MB-435 ADR cells by treating them with 0.2 µg/mL 
of Doxorubicin-HCl once a week. 
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In vitro transfection efficiency and cytotoxicity of PgP/pDNA complexes in breast cancer 
cells 
Transfection efficacies of PgP-12k, FA-PgP-12k and FA-PgP-12k MIX: Transfection 
efficiency of 3 different formulations of PgP-12k (PgP-12k, FA-PgP-12k, and FA-PgP-
12k MIX) were assessed by transfecting various breast cancer cell types with green 
fluorescent protein in media containing 10% serum. PEI/pDNA and FA-PEI/pDNA 
complexes at an N/P of 5/1 were also transfected as a positive control. Untreated cells 
were used as a negative control. Polyplexes were prepared by mixing PgP and pGFP, (2 
µg/mL) at 25/1 N/P ratio and then incubating them for 30 minutes at 37°C. Cells (9x 105 
cells/well) were seeded in 12-well plates and allowed to attach overnight. The cells were 
then incubated with PgP/pGFP complexes in media containing 10% serum for 24 hours. 
Cells were incubated for 4 hours in folate free media prior to transfection to starve folate 
receptors. Treatment groups designated with INHIB were changed to RPMI 1640 media 
containing 760 micromole/Liter (0.33 mg/mL) of free folate 10 minutes prior to 
transfection to block folate receptor alpha 
 
Afterward, the media was removed and replaced with fresh media containing 10 % FBS 
and cells were incubated an additional 24 hours. The GFP-expressing cells were imaged 
using an inverted fluorescence microscope. Following imaging, cells were trypsinized 
and GFP-expressing cells were counted using a flow cytometer. The results were 
expressed as a percentage of transfected cells. 
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Cytotoxicity was also analyzed by MTT assays in parallel experiments following the 
same transfection protocol. 48 hours post-transfection, cells were washed with PBS and 
incubated with 1 mL of serum-free media containing 240 µL of Thiazolyl Blue 
Tetrazolium Bromide in PBS (2 mg/mL) for 4 hours at 37 °C. After incubation, MTT-
containing medium was removed, and 1 mL of DMSO was added to dissolve the 
formazan crystals formed by live cells. Absorbance was measured at 570 nm using a 
Biotek Synergy HT plate reader. Cell viability was assessed according to the following 
formula: Cell viability (%) = (OD 570 (sample)/ OD 570 (control)) X 100%. Statistical analysis 
was performed using ANOVA for multiple comparisons using Tukey’s Post Hoc analysis 
using Dunnet’s correction. 
 
Comparison of transfection efficacies of PgP-12k, FA-PgP-12k and FA-PgP-12k MIX 
Three (FA+) breast cancer types: MCF-7, MDA-MB-435 wild type and its Doxorubicin 
resistant counterpart (ADR) and one (FA-) breast cancer MDA-MB-468, were utilized to 
test gene delivery performance in cancerous cells (Fig 1.1). The paired breast cancer set 
of wild type (FA+) MDA-MB-435 WT and ADR cells were assessed for candidacy in 
future experimentation involving targeted delivery of ABCB1 targeted siRNA.  
 
Serum aggregation plays a significant role in reducing the efficacy of non-viral delivery 
systems, often resulting in failure in vivo where protein accounts for approximately 7% of 
blood volume. 32,116 In order to simulate a more clinically relevant environment, 
transfections were performed in media containing 10% Fetal Bovine Serum (FBS). 
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The specificity of FA-functionalized PgP-12k/pGFP polyplex was determined by 
transfecting (FA+) MCF-7, MDA-MB-435 (WT,ADR) and (FA-) MDA-MB-468 with 
PgP-12k, FA-PgP-12k or FA-PgP-12k MIX, each complexed with pGFP at an N/P ratio 
of 25/1. FA conjugated PEI was used as a positive control. 	117 Cells were incubated for 4 
hours in FA free media prior to transfection to starve folate receptors. 
 
Inhibition of FA-PgP-12k and FA-PgP-12k MIX transfections with free folate 
Target specificity was further investigated by performing transfection in media 
containing 760 micromole/Liter free folate to act as a competitive inhibitor for folate 
receptor alpha specific uptake. Treatment groups designated with INHIB were changed to 
RPMI 1640 media containing 760 micromole/Liter (0.33 mg/mL) of free folate 10 
minutes prior to transfection to block folate receptor alpha. After 24 hours media was 
replaced to RPMI 1640 containing 10% FBS and 1% Penicillin.  Data acquisition 
occurred 48 hours post transfection using aforementioned techniques. 
 
Intracellular trafficking and nuclear localization study 
PgP-12k was conjugated with Rhodamine 123 in a manner similar to Yang et al.  118  
Rhodamine labeled PgP-12k was mixed with FA-PgP-12k (1/5 w/w ratio) for 
visualization. MDA-MB-435 WT and ADR cells (9x 105 cells/dish) were plated in 
Fluorodishes. Polyplexes were formed by mixing pGFP and Rhodamine labeled PgP at 
N/P ratio of 25/1 and transfected as described above. Cells were fixed using 4% 
paraformaldehyde solution at 36 hours post transfection and nuclei were counter stained 
 95 
with DAPI. Cells were imaged using an Olympus IX81 confocal microscope with 
Hamamatsu DCAM Camera using Metamorph image processing software. 
 
Determination of the driver of PgP toxicity 
Transfections investigating the efficacy in delivering pDNA were fixed to an equal dose 
of plasmid; an increase in number of micelles would also decrease average plasmid 
content per polyplex. PEI toxicity and performance is driven by free amine content. With 
this in mind two additional forms of DDV toxicity were investigated: 1) All PgP 
polyplexes were formed at 25/1 N/P ratio and diluted 2) uncomplexed PgP; each regime 
was tested at equivalent N/P 5/1, 15/1, 25/1 PgP transfection doses. Confirmation of 
differences in toxicity related to increase in primary amine exposure is necessary in the 
event cellular exposure is restricted to only free, uncomplexed micelle populations.  
These investigations will help elucidate the primary driver of DDV cytotoxicity and 
provide further support of PgP as a potential gene and drug delivery agent.  
 
Doxorubicin loading in FA-PgP 
Hydrophobic Doxorubicin freebase was dissolved into methanol to form a 10 mg/mL 
solution and then serially diluted. One hundred µl of various concentrations of DOX 
solution was added to 1 mg/mL FA-PgP and FA-PgP MIX solutions and shaken for 4 
hours at 37 degrees. Samples stood at 37 degrees overnight to allow methanol to 
evaporate. The solution was filtered using a 0.2 um filter to remove unloaded DOX. DOX 
loaded PgP (DOX/PgP) samples were then analyzed at 480nm absorbance and the 
amount of DOX loaded in PgP was calculated using a DOX standard curve. Loading 
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efficiency and percent loaded by weight were determined in triplicate. Samples were then 
frozen for further use. 
 
Cytotoxicity of Doxorubicin-loaded folate-functionalized poly-(lactide-co-glycolide)-g-
poly(ethylenimine) in various breast cancer cells 
Polyplexes were prepared by mixing PgP-12k, FA-PgP-12k, or FA-PgP MIX, with pGFP 
(1 µg) at a N/P ratio of 25/1 and then allowing them to incubate for 30 minutes at 37°C. 
Cells (2.25x 105 cells/well) were plated in 48-well plates and allowed to attach overnight. 
The cells were incubated with PgP, DOX/PgP, PgP/pDNA or DOX/PgP/pDNA in media 
containing 10% serum for 48 hours, at which point, media was replaced to 0.25 mL of 
serum-free media containing 60 µL of MTT solution (2 mg/mL Thiazolyl Blue 
Tetrazolium Bromide in PBS) and incubated for 4 hours at 37 degree. Doses apportioned 
via polymer concentrations at each N/P of PgP (5/1, 15/1, 25/1) using 0.5 µg pGFP/well; 
polyplexes formed at N/P ratio of 25/1 then subsequently diluted down to match polymer 
concentrations at lower N/P ratio equivalent transfections. DOX HCl was used as control 
and the dose is equivalent to amount of DOX loaded by DOX/PgP at specified N/P ratio. 
 
Uptake of folate-functionalized poly(lactide-co-glycolide) -graft-polyethylenimine/siGLO 
nanoparticles (FA-PgP) in MDA-MB-435 ADR breast cancer cells 
The siGLO Red transfection indicator, consisting of a fluorescently labeled siRNA 
duplex with a chemical modification for nuclear localization, was used to evaluate siRNA 
transfection efficiency. PgP/siGLO complexes (1 µg siGLO Red) at various N/P ratio 
were transfected in cells in 10% serum condition. PEI/siGLO at N/P 5/1 was used as 
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positive controls. The cells were incubated at 37 °C for 24 hours and then the media were 
replaced with fresh media containing 10 % FBS. At 4 and 24 hours post-transfection, 
siGLO Red-transfected cells were collected and assessed by flow cytometry and the 
results expressed as % uptake positive. Groups designated with “INHIB” were co 
incubated with (0.33 mg/mL free folate) during transfection. 
 
Doxorubicin-loaded folate-functionalized poly (lactide-co-glycolide) -graft-
polyethylenimine nanoparticles (FA-PgP) as drug and siRNA carrier for combinatorial 
therapy for the efficient treatment of MDA-MB-435 ADR breast cancer cells 
A siRNA knockdown study was performed in which the cell viability of various N/P 
ratios of ABCB1 targeted or scrambled siRNA complexes (1 µg siRNA/48 well) in 
MDA-MB-435 (ADR) cells. Cells were transfected and 48 hours post transfection media 
containing 50 µg/mL Doxorubicin was added to specified group. At 96 hours, post 
transfection, % knockdown was assessed via RT-PCR while cell viability was assessed 
via MTT to compare differences in metabolic activity. 
 
Statistical analysis 
Statistical analysis was performed using ANOVA for multiple comparisons using 
Tukey’s Post Hoc analysis unless otherwise noted. A p-value of less than 0.05 was 
considered statistically significant. The data were represented as mean + SEM. 
 
Results and Discussion 
The structure of FA-PgP was characterized by 1H NMR (300 MHz, D20). Presence of 
folate related peaks (6-8.6 ppm) represent indicate successful synthesis (Fig 5.2). 	119 UV 
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spectroscopy indicated FA-PEG conjugation to 1 in 12.5 molecules of PgP-12k (data not 
shown). 
 
 
Figure 5.2: 1H-NMR spectra of FA-PgP-12k 
 
 
Minimum N/P ratios required for complex formation between PgP and pDNA were 
investigated using a gel retardation assay. PgP/pDNA complexes were formed at a 
variety of N/P ratios and the minimum ratio for complex formation was determined by 
identifying the lowest N/P ratio at which no pDNA migration was observed, 
demonstrating complete binding of free pDNA by PgP.  
-CH	of	PLGA		
-CH2	of	PLGA		
-CH3	of	PLGA	
-CH2	of	PEI	and	PEG		
Folic	Acid	
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Figure 5.3: Gel retardation assay using PgP-12k, FA-PgP-12k, one part FA-PgP-12k to 
two parts PgP-12k by weight, and one part FA-PgP-12k to four parts PgP-12k by weight 
/pGFP complexes. Lane 1: DNA ladder, Lane 2:naked pDNA, Lane 3 -9: PgP/pGFP 
(N/P: 2.5, 5, 7.5, 10, 12.5, 15, 17.5 respectively) 
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Ratios at which complete binding is observed: PgP-12k N/P (2.5/1), FA-PgP-12k N/P 
(5/1), one part FA-PgP-12k to two parts PgP-12k by weight N/P (5/1), and one part FA-
PgP-12k to four parts PgP-12k by weight N/P (5/1) (Fig 5.3).  
 
 
Figure 5.4a: Heparin competition assay using PgP-12k, FA-PgP-12k, one part FA-PgP-
12k to two parts PgP-12k by weight, and one part FA-PgP-12k to four parts PgP-12k by 
weight /pGFP /pGFP complexes. Lane 1: DNA ladder, Lane 2:naked pDNA, Lane 3: 
PgP/pGFP (N/P:15/1), Lanes 4-10: PgP-12k/pGFP (N/P: 15/1 with W/W Heparin 1, 2, 5, 
10, 20, 40, 100 respectively) 
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Figure 5.4b: Heparin competition assay using PgP-12k, FA-PgP-12k/pGFP complexes 
N/P 30/1 Lane 1: DNA ladder, Lane 2:naked pDNA, Lane 3: PgP/pGFP (N/P:30/1), 
Lanes 4-10: PgP-12k/pGFP (N/P: 30/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 
respectively)  
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Figure 5.4c: FA-PgP-12k and one part FA-PgP-12k to two parts PgP-12k by 
weight/pGFP complexes. Lane 1: DNA ladder, Lane 2:naked pDNA, Lane 3: PgP/pGFP 
(N/P:25/1), Lanes 4-10: PgP-12k/pGFP (N/P: 25/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 
100 respectively) 
 
For the heparin competition assay, PgP-12k, FA-PgP-12k, one part FA-PgP-12k to two 
parts PgP-12k by weight, and one part FA-PgP-12k to four parts PgP-12k by weight all 
formed at N/P 15/1 and subjected to various relative weights of Heparin, complete 
dissociation occurred at 5/1 for all permutations (Fig 5.4A). Using polyplexes formed at 
N/P 30/1, PgP-12k, FA-PgP-12k/pGFP polyplexes lose their cargo when subjected to a 
weight-to-weight treatment of Heparin at W/W 10/1 (Fig 5.4B). A similar experiment 
using one part FA-PgP-12k to two parts PgP-12k by weight, and one part FA-PgP-12k to 
four parts PgP-12k by weight all formed at N/P 25/1 also required a Heparin dose W/W 
10/1 to dissociated cargo (Fig 5.4C). 
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Figure 5.5: Gel retardation assay using PgP-12k, FA-PgP-12k, one part FA-PgP-12k to 
two parts PgP-12k by weight, and one part FA-PgP-12k to four parts PgP-12k by weight 
/siABCB1 complexes. Lane 1: DNA ladder, Lane 2:naked siABCB1, Lane 3 -9: 
PgP/siABCB1 (N/P: 2.5, 5, 10, 12.5, 15, 17.5, 20, 22.5, 25 respectively) 
 
Minimum N/P ratios required for complex formation between PgP and siRNA were 
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variety of N/P ratios and the minimum ratio for complex formation was determined by 
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identifying the lowest N/P ratio at which no siABCB1 migration was observed, 
demonstrating complete binding of free siABCB1 by PgP (Fig 5.5).  
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Figure 5.6a: Heparin competition assay using PgP-12k, FA-PgP-12k, one part FA-PgP-
12k to two parts PgP-12k by weight, and one part FA-PgP-12k to four parts PgP-12k by 
weight / siABCB1 complexes. Lane 1: DNA ladder, Lane 2:naked siABCB1, Lane 3: 
PgP/ siABCB1 (N/P:15/1), Lanes 4-10: PgP-12k/ siABCB1 (N/P: 15/1 with W/W 
Heparin 1, 2, 5, 10, 20, 40, 100 respectively) 
 
 106 
 
Figure 5.6b: Heparin competition assay using PgP-12k/ siABCB1 complexes. Lane 1: 
DNA ladder, Lane 2:naked siABCB1, Lane 3: PgP/ siABCB1 (N/P:30/1), Lanes 4-10: 
PgP-12k/ siABCB1 (N/P: 30/1 with W/W Heparin 1, 2, 5, 10, 20, 40, 100 respectively) 
 
 
 
Figure 5.6c: Heparin competition assay using PgP-12k, FA-PgP-12k / siABCB1 
complexes. Lane 1: DNA ladder, Lane 2:naked siABCB1, Lane 3: PgP/ siABCB1 
(N/P:60/1), Lanes 4-10: PgP-12k/ siABCB1 (N/P: 60/1 with W/W Heparin 1, 2, 5, 10, 20, 
40, 100 respectively) 
 
Co
nt
ro
l	
0	 1	 2	 5	 10	 20	
Heparin/siRNA	
(Weight	ra:o)	 40	
PgP-12K	
100	(B) 
Co
nt
ro
l	
0	 1	 2	 5	 10	 20	
Heparin/siRNA	
(Weight	ra:o)	 40	
PgP-12K	
FA-PgP-12K	
100	(C) 
 107 
Ratios at which complete binding is observed: PgP-12k N/P (15/1), FA-PgP-12k (N/P 
17.5/1), one part FA-PgP-12k to two parts PgP-12k by weight (12.5/1), and one part FA-
PgP-12k to four parts PgP-12k by weight N/P (12.5/1). When compared to pDNA results 
it requires 2-6.5x the concentration of PgP to fully bind siRNA.  
 
For the heparin competition assay, PgP-12k, FA-PgP-12k, one part FA-PgP-12k to two 
parts PgP-12k by weight, and one part FA-PgP-12k to four parts PgP-12k by weight all 
formed at N/P 15/1 and subjected to various relative weights of Heparin, complete 
dissociation occurred at 1/1 for all permutations (Fig 5.6A). Compared to pDNA, siRNA 
dissociated using ~1/10 the Heparin. Taken with gel retardation data this indicates that 
pDNA binds more readily and more strongly to PgP than does siRNA. To investigate this 
concept further, PgP-12k/siABCB1 polyplexes were formed at N/P 30/1 (Fig 5.6B). PgP-
12k/siABCB1 polyplexes lose their cargo when subjected to a weight-to-weight treatment 
of Heparin at W/W 2/1 or about double the weight required to dissociate PgP-
12k/siABCB1complexes formed at one half the N/P ratio (15/1) suggesting a linear 
relationship. However, in another experiment, this time using PgP-12k and FA-PgP-12k 
formed at N/P 60/1 also required a Heparin dose W/W 10/1 to dissociated cargo (Fig 
5.6C). In other words, double the concentration of PgP in 60/1 required 5x more expected 
Heparin by weight. This additional weight may be required as a result of higher average 
number of stable micelles over time associated with higher N/P, potentially another 
example of kinetic stability having an appreciable effect over experimental timeframes. 
Perhaps, some unknown factors resulting in a higher charge densities per micelle or 
greater number of micelles than to be expected from a linear increase, resulting in a 
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disproportional strength of binding. The similar performance of PgP-12k, FA-PgP-12k 
and its blends suggest that FA conjugation has little effect on the binding kinetics as all 
polyplexes exhibited the ability to dissociate from pDNA and siRNA at a similar Heparin 
concentration, demonstrating the potential utility of PgP for delivery and release of 
nucleic acid cargo.  
 
 
Figure 5.7: (A) Hemolytic activity of PEI, PgP-12k, and FA-PgP-12k at 0.025, 0.05, 0.1, 
0.25, 0.5, 0.75, 1 mg/mL in 7.4 pH 150 mM phosphate buffered saline (PBS). Red blood 
cells collected from Sprague-Dawley rats. (B) Hemoaggregation of red blood cells in 7.4 
pH 150 mM PBS incubated with 1 mg/mL of PEI, PgP-12k, or FA-PgP-12k for fifteen 
minutes 
 
Hemolysis is a direct measure of cytotoxicity on erythrocytes, while hemoaggregation 
provides insight into the physical interactions of the delivery vehicle with solid elements 
in the blood. Both are important factors necessary to assess the safety of the delivery 
vehicle prior to in vivo evaluation. Interestingly, increasing the dose of PgP at any MW 
between the concentrations 0.025 mg/mL to 0.5 mg/mL did not result in increased 
hemolysis, as was demonstrated with PEI. PgP-12k and FA-PgP-12k induced little to no 
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hemolytic activity with differences from control only occurring at 0.05, 0.25, and 0.75 
mg/mL for FA-PgP-12k and 0.25 for PgP-12k albeit statistically significant due to tight 
grouping of values (Fig 5.7A). FA-PgP-12k exhibited similar hemoaggregation properties 
to PgP-12k. Aggregation is limited especially compared to the high level of 
hemoaggregation and hemolysis induced by an equal concentration of PEI (Fig 5.7B). 
Again, there is little difference in the performance between PgP-12k and FA-PgP-12k 
suggesting that conjugation of FA to PgP-12k has little effect on overall physicochemical 
characteristics.  
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Figure 5.8: Transfection efficiency of PEI, FA-PEI (N/P: 5/1), PgP-12k/pGFP, FA-PgP-
12k/pGFP, mixed micelles comprised of one part FA-PgP-12k to two parts PgP-12k by 
weight, (N/P: 25/1) in (A) MCF-7, (B) MDA-MB-468, (C) MDA-MB-435 Wild Type, 
and (D) MDA-MB-435 ADR cells. Groups designated with “INHIB” were co incubated 
with (0.33 mg/mL free folate)  * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 
 
Folate functionalized PgP-12k maintained high levels of significant transfection in all 
(FA+) MCF-7, MDA-MB-435 (wild type, Doxorubicin resistant variant) cells lines albeit 
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reduced compared to PgP-12k (Fig 5.8). FA-PgP-12k weight used exceeds PgP-12k at 
same N/P since FA has some additional non-contributing weight of PEG spacer and FA. 
Thus amount used in transfections are as follows: PgP-12k < FA-PgP-12k MIX < FA-
PgP-12k. This adds more evidence to the concept of PgP-12k concentration driving 
transfection increase, as a higher concentration of FA-PgP-12k was used with less 
resulting transfection compared to PgP-12k. 
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Figure 5.9: Metabolic activity of PEI, FA-PEI (N/P: 5/1), PgP-12k/pGFP, FA-PgP-
12k/pGFP, mixed micelles comprised of one part FA-PgP-12k to two parts PgP-12k by 
weight/pGFP, (N/P: 25/1) in (A) MCF-7, (B) MDA-MB-468, (C) MDA-MB-435 Wild 
Type, and (D) MDA-MB-435 ADR cells. Groups designated with “INHIB” were co 
incubated with (0.33 mg/mL free folate)  * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** 
P≤0.0001 
 
Significant cytotoxicity was induced in PgP-12k groups in both MCF-7 and MDA-MB-
468 cells; with additional significant cytotoxicity in FA-PgP-12k MIX and FA-PgP-12k 
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INHIB groups in MDA-MB-468 cells (Fig 5.9). More substantial reduction in 
transfection percentage was noted in (FA-) MDA-MB-468, potentially the result of 
reduced presence of folate receptor alpha (Fig 5.10).  
 
   
Figure 5.10: Transfection efficiency of PgP-12k/pGFP, FA-PgP-12k/pGFP and mixed 
micelles comprised of one part FA-PgP-12k to two parts PgP-12k by weight/pGFP (N/P: 
25/1) complexes in (A) MCF-7 (B) MDA-MB-468 (C) MDA-MB-435 wild type (D) 
MDA-MB-435 Doxorubicin resistant variant. * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** 
P≤0.0001 vs control. * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 vs FA-PgP-12k 
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The decrease in transfection efficacy observed with FA-PgP is likely due to folate related 
steric hindrance or altered endosomal release dynamics, as a mixed micelle formulation 
restored performance in a PgP-12k proportional manner, a phenomena noted in Cheng et 
al.120 
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Figure 5.11: Transfection efficiency of FA-PgP-12k/pGFP and mixed micelles comprised 
of one part FA-PgP-12k to two parts PgP-12k by weight/pGFP (N/P: 25/1) complexes in 
(A) MCF-7 (B) MDA-MB-468 (C) MDA-MB-435 wild type (D) MDA-MB-435 
Doxorubicin resistant variant. Groups designated with “INHIB” were co incubated with 
(0.33 mg/mL free folate). * : P<0.01 * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 
vs FA-PgP-12k, * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 vs FA-PgP-12k Mix 
mixed micelles comprised of one part FA-PgP-12k to two parts PgP-12k by weight 
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The presence of FA moiety resulted in a substantial drop in transfection efficiency for all 
cells, indicating some kind pathway specific or deterministic uptake. Reduction of FA-
PgP content in micelle system did not impede folate receptor alpha specific uptake, as 
mixed micelle exhibited equitable levels of inhibition of transgene expression in the 
presence of free folate compared to its fully functionalized counterpart in all (FA+) 
groups (Fig 5.11). There was no statistical difference between FA-PgP-12k groups and 
their free folate inhibited counterparts in (FA-) MDA-MB-468 groups. Reduced, but not 
statistically significant inhibition was noted in FA-PgP-12k free folate inhibited groups in 
MDA-MB-435 Wild Type cells compared to its uninhibited counterpart, partially a 
byproduct of higher variability associated with higher transfection percentages. Reduced 
differences in transfection percentage in (FA-) cells compared to the more dramatic and 
in most cases, statistically significant inhibition of transgene expression in (FA+) groups 
further supports a degree of pathway specificity related to folate receptor alpha presence.  
 
Differences in cell lines are result of differences in uptake and subsequent intracellular 
trafficking. The size distribution of polyplexes is a dynamic entity related to synthetic 
composition, initial formation conditions, temperature, pH, protein and salt contents. 9 
Serum content is high in albumin, whose presence has been shown to have a strong 
detrimental effect on the kinetic stability of polymeric delivery due to induced 
aggregation effects and formation of a ternary structure. 102,108 Differences in media 
composition may have some effect on the aggregation but stronger effects are likely due 
to serum content, which remains constant throughout experimentation. These minute 
differences in size and charge may have more profound effects depending on each cell’s 
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optimal trafficking modality. Altering the relative proportion of polyplexes trafficked to 
each endocytic pathway will have obvious effects dependent on the efficacy of each 
route, with optimal pathway conditions likely varying between cell lines.36  
 
Furthermore, cells that divide more quickly have been associated with improved 
transfection outcomes. Nuclear import and subsequent transcription are two rate limiting 
steps to transfection. 77,109 Nuclear pores generally only allow free trafficking of 
molecules under 9 nm in diameter or 50kD in size, much smaller than the observed size 
of polyplexes. 83,101 Magnitudes higher transfections have been associated with S or G2/M 
phases compared to other cell cycles. 110 During these phases genetic material is no longer 
sequestered within the nuclear envelope, thus it is now widely accepted that increased 
cell division and growth have a positive correlation with transfection success. 36 
Generally observed cell division rates increase across MDA-MB-435 ADR, MDA-MB-
468, MCF-7, and MDA-MB-435 WT cells. This observation may serve to explain some 
of the resulting transfection differences.  
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Figure 5.12: Intracellular trafficking of Rhodamine-PgP-12k/FA-PgP-12k/pGFP 
complexes in MDA-MB-435 wild type cells a) 24 hours and b) 48 hours post transfection 
 
Intracellular uptake, nuclear localization and subsequent transfection were observed in 
both MDA-MB-435 Doxorubicin resistant variant breast cancers via confocal microscopy 
24 and 48 hours post transfection (Fig 5.12). Intracellular uptake, nuclear localization and 
subsequent GFP production occurs in a visually similar pattern to PgP-12k (Fig 3.7). 
There is little apparent difference in intercellular trafficking and nuclear localization 
between base PgP-12k and FA-PgP-12k.  
 
A fixed mass (1 mg/mL) of each PgP type was dissolved to a fixed volume (1 mL) and 
subjected to variable hydrophobic Doxorubicin content.  
 
 
 
a	 b	
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% Loaded by Weight % Efficiency 
PgP-12k 31.85 21.23 
FA-PgP-12k 30.47 20.31 
FA-PgP-12k MIX 30.34 20.22 
Table 5.1: Table summarizing Doxorubicin loading in PgP-12k, FA-PgP-12k, and mixed 
micelles comprised of one part FA-PgP-12k to two parts PgP-12k by weight 
 
Values shown in Table 5.1 exhibit the content of DOX loaded in PgP-12k, FA-PgP-12k 
and FA-PgP-12k MIX micelles and associated efficiency, constrained by maximum 
solubility of DOX in methanol for chosen loading scheme.  
 
Hydrophobic weight in each type of PgP is intrinsic to it composition, with slightly 
reduced composition of PLGA percentage by weight found in functionalized groups due 
to the weight of folate and PEG spacer. Table 5.1 describes the relative molar ratios of 
PLGA content across loading conditions with little difference noted between FA-PgP-12k 
and FA-PgP-12k MIX groups. 
 
In chapter 4, it was found larger PgPs are more toxic per weight, regardless of N/P 
relationship. In chapter 5 it was then determined this concept carries forward to it DOX 
loaded counterparts. Confirmation that dose is more critical than form will again be 
sought in FA-conjugated Pg-12k and will be investigated in both manners. 
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Figure 5.13: Cytotoxicity of Doxorubicin HCl, FA-PgP-12k and mixed micelles 
comprised of one part FA-PgP-12k to two parts PgP-12k by weight, FA-PgP-12k and 
mixed micelles comprised of one part FA-PgP to two parts PgP-12k by weight/pGFP 
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complexes, DXR (Figure 5.13 caption, continued) loaded FA-PgP and Doxorubicin 
loaded mixed micelles comprised of one part FA-PgP-12k to two parts PgP-12k by 
weight, Doxorubicin loaded FA-PgP-12k and Doxorubicin loaded mixed micelles 
comprised of one part FA-PgP-12k to two parts PgP-12k by weight/pGFP complexes in 
(A) MCF-7, (B) MDA-MB-435 Wild Type, and (C) MDA-MB-435 ADR cells (top row 
to bottom row respectively). Concentration of Doxorubicin HCl used was equivalent to 
amount of Doxorubicin used in DOX loaded PgP groups. PgP/pGFP complexes were 
formed at N/P 25/1 and both PgP alone and PgP/pGFP complexes were diluted down to 
concentration of PgP found in designated N/P equivalent. * P≤ 0.05, ** P≤0.01, *** 
P≤0.001, **** P≤0.0001 vs control, * P≤ 0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 
vs equivalent PgP or PgP/pGFP group, éP≤ 0.05, éé P≤0.01, ééé P≤0.001, 
éééé P≤0.0001 vs equivalent DOX HCl dose 
 
Statistically significant cytotoxicity was induced by FA-PgP-12k in both forms at 25/1 
equivalent dose and FA-Pgp-12k Mix groups at 15/1 and 25/1 equivalent doses in MDA-
MB-435 Wild Type cells and 25/1 in MDA-MB-435 ADR cells. Interestingly, there was 
a statistically significant increase in metabolic activity in FA-PgP-12k at the equivalent 
PgP dose of a 5/1 transfection in MDA-MB-435 ADR cells. All DOX loaded groups 
were significantly cytotoxic relative to their unloaded counterparts except DOX/FA-PgP-
12k/pGFP at 5/1 dose in MDA-MB-435 Wild Type and all DOX loaded groups tested in 
MDA-MB-435 ADR cells. All DOX/FA-PgP-12k groups and DOX/FA-PgP-12k Mix at 
5/1 equivalent dosage in MDA-MB-435 ADR cells were found to induce an increase in 
overall metabolic activity over comparable DOX HCl groups. In MDA-MB-435 ADR 
increased cell viability is induced by FA-PgP-12k at 5/1 equivalent dose with similar 
elevated metabolic activity in DOX Loaded counterparts, this trend extends into 
DOX/FA-PgP-12k/pGFP at 10/1 equivalent dosage (Fig 5.13). 
 
PgP-12k permutations were discussed in detail in chapter 3 but their graphs are shown 
here to illustrate the similarities in metabolic across dose and form between FA-PgP-12k, 
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FA-PgP-12k MIX, and PgP-12k groups, again further emphasizing the greater 
importance of dose over form in context of PgP.  
 
 
Figure 5.14: Cell uptake of siGLO/FA-PgP-12k and of one part FA-PgP-12k to two parts 
PgP-12k by weight (N/P: 25/1) complexes in MDA-MB-435 ADR cells 4 and 24 hours 
post transfection. Groups designated with “INHIB” were co incubated with (0.33 mg/mL 
free folate). (A)% uptake (B) mean fluorescence value (F). * P≤ 0.05, ** P≤0.01, *** 
P≤0.001, **** P≤0.0001 vs FA-PgP-12k MIX, P<0.01 * P≤ 0.05, ** P≤0.01, *** 
P≤0.001, **** P≤0.0001 vs FA-PgP-12k. 
 
Although mitigation of transfection efficacy with free folate supports some degree of 
uptake pathway specificity, confirmation of reduction of uptake would further support 
this theory. In a siGLO uptake experiment in MDA-MB-435 ADR cells, FA-PgP-
12k/siGLO polyplex uptake and mean fluorescence was higher than FA-PgP-12k 
MIX/siGLO polyplexes (Fig 5.14). Greater uptake noted in FA-PgP-12k over FA-PgP-
12k MIX groups is interesting since elevated cytotoxicity and transfection efficacy is 
noted in FA-PgP-12k MIX groups. In the presence of free folate, FA-PgP-12k/siGLO 
polyplexes induces lower transfection and mean brightness, suggesting reduction of FA 
receptor related trafficking of folate functionalized PgP-12k is at least partially 
responsible for lower transgene expression, with other differences resulting in differences 
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in trafficking, endosomal escape, or nuclear localization. Since less FA-PgP-12k 
MIX/siGLO is shown to be taken up by cells than with FA-PgP-12k, the increase in 
transfection efficiency is likely due to more favorable outcomes in intracellular 
trafficking, endosomal escape, or nuclear localization, at least in MDA-MB-435 ADR 
cells. Further research is warranted but identification and relative positioning of critical 
factors is the first step in being able to compare DDV systems across contexts. 
 
 
Figure 5.15: Metabolic activity in MDA-MB-435 ADR cells after knockdown with 
ABCB1 targeted or scrambled siRNA polyplexes. RNAiMAX, PEI, PgP-12k, or FA-
PgP-12k/siRNA (N/P) polyplexes with and without 50 µg/mL DOX treatment. 
 
The accepted practice of siRNA validation dictates that the delivery vector be confirmed 
to not effect off-target mRNA levels, as to mitigate unintended side effects. A siRNA 
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knockdown study was performed in which the cell viability of various N/P ratios of 
ABCB1 targeted or scrambled siRNA complexes (1 µg siRNA/48 well) in MDA-MB-
435 (ADR) cells. Cells were transfected and 48 hours post transfection media containing 
50 µg/mL Doxorubicin was added to specified group. At 96 hours, post transfection, % 
knockdown was assessed via RT-PCR while cell viability was assessed via MTT to 
compare differences in metabolic activity. Non-targeted PgP-12k groups effects altered 
endogenous GAPDH levels to an unwanted degree, invaliding RT-PCR quantification, 
however there were significant differences found between cell viabilities. In groups not 
dosed with Doxorubicin only RNAiMAX was found to be more cytotoxic than the no 
treatment control (Fig 5.15). Both PEI 5/1 and PgP-12k 10/1 groups induced cell 
viabilities over control in a significant fashion, potentially as a result of induced 
knockdown, general or MDR1 specific. All DOX dosed groups were found to be 
significantly different from the non-treated control (p≤ 0.0001) and all DOX treated 
groups were found to be statistically different than their non-treated counterparts, 
indicating significant cytotoxicity induced by DOX treatment (p≤ 0.0001). Compared to 
DOX treated control: RNAiMAX, PEI 5/1, PgP-12k 10/1, PgP-12k 15/1, and PgP-12k 
20/1, ABCB1-targeted groups were all found to have significantly reduced metabolic 
activity (p≤ 0.0001, p≤ 0.0001, p=0.0037, p=.0006, and p≤ 0.0001 respectively). PgP-12k 
10/1 and FA-PgP-12k MIX increased DOX related cytotoxicity but not in a significant 
fashion. Non-targeting PgP-12k at N/P 20/1 also did not induce DOX related cytotoxicity 
and was found have higher metabolic activity than the DOX dosed control. While RT-
PCR studies were unable to indicate if ABCB1 knockdown in ABCB1 targeted groups 
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was specific or generic but increased cytotoxicity in ABCB1 groups relative to non-
targeted group (p≤ 0.0001), does support at least some degree of therapeutic efficacy.       
 
Altogether, this suggests that a variety of therapeutically relevant PgP target/gene/drug 
configurations are yet to be investigated. The development of PgP as a lyophilizable 
system will begin to address shelf life and production issues while maintaining the 
standard format, accomplished by DDV reconstitution and subsequent administration via 
intravenous injection. Development of this system will strike a balance between the 
realities of medicine today with the potential of the personalized treatments of tomorrow. 
This incorporation of genetic and targeting technologies in a product that in a familiar 
format to practitioners will ease the transition, adoption and incorporation of 
nanotherapeutics drug delivery vehicles into the clinical workspace. 
 
It was unclear if inhibition with free FA resulted in decreased uptake along with 
decreased transfection so an experiment was performed to determine uptake; PgP-12k 
uptake did in fact increase with FA-moiety conjugation. Furthermore, there is decreased 
uptake with increased presence of competitive moiety (free folate) which corroborates 
decreased percentage transfected in FA blocked transfection experiments. These trends 
however, are contingent on reasonable presence of FA receptor alpha, which is present in 
higher levels in MCF-7 and MDA-MB-435 groups but in lower levels in MDA-MB-468 
groups. 
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Conclusions 
PgP-12k has illustrated the greatest versatility as a multifunctional drug delivery 
platform, out of tested PgP weights. High levels of transfection with low levels of 
cytotoxicity were observed in PgP-12k experiments. Adequate drug loading performance 
with the ability to undergo industry preferred 0.2 micron filter based purification was 
noted in PgP of all weights with DOX loading content being most closely related to 
PLGA content. With this in mind, lower transfection efficacies associated with PgP-25k 
and PgP-50k may be redeemed by higher levels of DOX loading per weight. 
Functionalization with FA in PgP-12k only marginally effects physicochemical 
properties including DOX loading compared to base PgP-12k while imbuing some folate 
receptor alpha receptor related specificity to DDV. Plasmid DNA completely binds with 
PgP-12k and FA-PgP-12k more strongly with less polymer compared to siRNA 
indicating that for siRNA applications, higher concentrations of PgP may need to be 
used. While loss of function induced by ABCB1 siRNA have shown to make drug 
resistant phenotypes more susceptible to chemotherapeutics and combined with target 
specificity represents a potential therapy, production of a therapeutic protein with pDNA 
transfection may be a better application of PgP. Further investigation into the transgene 
expression of individual cells will help quantify the potential of gain of function therapies 
as well as help better understand the dynamics behind in loss of function if that is the 
desired modality. Based on this pilot study, new combinations of therapeutically relevant 
nucleic acids and drugs with PgP warrant further investigation. 
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